<!DOCTYPE html>
	<html class="sl-root decks export offline loaded">
	<head>
		<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
		<meta charset="utf-8">
		<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
		<title>Module 2: Crises in New Antibiotic Development</title>

		<meta name="description" content="Module 1. 97039-Global Heath, Antimicrobial Drugs and Vaccines">

		<link rel="stylesheet" type="text/css" href="lib/offline-v2.css">



		<!-- User CSS -->
		<style id="user-css-output" type="text/css">
			.reveal .slides h1,
.reveal .slides h2,
.reveal .slides h3 {
  font-family: "Roboto";
}
.reveal .slides {
  font-family: "Roboto";
}

		</style>
	</head>
	<body class="reveal-viewport theme-font-opensans theme-color-white-blue">
		<div class="reveal">
			<div class="slides">
				<section data-id="b249f0d9a560e1ed4c81158e2ce828a6" data-auto-animate=""><div class="sl-block" data-block-type="text" style="width: 916px; left: 42px; top: 26px; height: auto;" data-block-id="afc739ccf0a3cfcd4a72a8076d63e471" data-name="text-dcf7a0">
<pwa-container-wrapper></pwa-container-wrapper><div class="sl-block-content" data-placeholder-tag="h1" data-placeholder-text="Title Text" style="z-index: 10; color: rgb(152, 0, 0); text-align: left; font-size: 90%;">
<h3><strong><span style="font-size:0.9em">97039: Global Health, Antimicrobial Drugs and Vaccines</span></strong></h3>
</div>
</div>
<div class="sl-block" data-block-type="text" data-name="text-8c1fbd" data-block-id="3ff9c31040d5941d657f671d447120af" style="height: auto; width: 974px; left: 42px; top: 78px;">
<pwa-container-wrapper></pwa-container-wrapper><pwa-container-wrapper></pwa-container-wrapper><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; text-align: left; color: rgb(152, 0, 0);" dir="ui">
<p><span style="font-size:1.0em"><em>Module 2:<strong> </strong></em></span><span style="font-size:1.0em"><em>The Crises of New Antibiotic Development</em></span></p>
</div>
</div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 974px; left: 50px; top: 249px;" data-block-id="c269df4aa7290669ea5b9e8d14166a2d" data-name="text-f1a148">
<pwa-container-wrapper></pwa-container-wrapper><pwa-container-wrapper></pwa-container-wrapper><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; text-align: left; line-height: 0.91;" data-has-line-height="">
<p><strong><span style="font-size:0.9em">Russell Lewis, Associate Professor</span></strong></p>

<p><span style="font-size:0.7em">Infectious Diseases, IRCSS S. Orsola-Malpighi Hospital</span></p>

<p><span style="font-size:0.7em">Department of Medical and Surgical Sciences</span></p>

<p><span style="font-size:21px">russeledward.lewis@unibo.it</span></p>
</div>
</div>
<div class="sl-block" data-block-type="image" data-name="image-33da42" data-block-id="9c9e165a21909c326061707e77274d18" style="width: 72.189px; height: 72px; left: 858.906px; top: 432px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 13; opacity: 0.75;"><div class="sl-block-content" style="z-index: 13;"><img style="" data-natural-width="382" data-natural-height="381" data-lazy-loaded="" data-src="global_antimicrobial_resistance/ab0483cf27bb4fb9563771275437412b.svg"></div></div></div>
<div class="sl-block" data-block-type="text" data-name="text-f3ea04" data-block-id="de3e25166b49ce1376089441f16424a4" style="height: auto; width: 210px; left: 790px; top: 516.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 14; line-height: 0.325;" data-has-line-height="">
<p><span style="color:#B22222"><span style="font-size:0.5em">Alma Mater Studiorum </span></span></p>

<p><span style="color:#B22222"><span style="font-size:0.5em">Università di Bologna</span></span></p>
</div></div>
</section><section data-id="c3d5f2ae7f931e0512c43a48f6a5b40e" data-auto-animate=""><div class="sl-block" data-block-type="text" style="width: 860px; left: 53px; top: 24px; height: auto;" data-block-id="b16a0977a1ea1bd31058e361adddcd19" data-name="text-a80170"><div class="sl-block-content" data-placeholder-tag="h2" data-placeholder-text="Title Text" style="z-index: 10; color: rgb(34, 34, 34);">
<h3 style="text-align:left"><strong><span style="color:#B22222">Learning objectives</span></strong></h3>
</div></div>
<div class="sl-block" data-block-type="text" style="width: 892px; left: 32px; top: 144px; height: auto;" data-block-id="180ef5203100f74f60684e2bcbeaddf7" data-name="text-7725e9" data-auto-animate-easing="ease"><div class="sl-block-style" style="z-index: 11; transform: rotate(0deg);"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; line-height: 1.43;" dir="ui" data-has-line-height="">
<ul>
	<li style="font-size:27px; text-align:left">Discuss factors contributing to the lack of antibiotic development</li>
	<li style="font-size:27px; text-align:left">Compare and contrast economic incentives proposed to enhanced antibiotic development</li>
	<li style="font-size:27px; text-align:left">Examine challenges in ensuring antibiotic access in low and middle income countries (LMICs)</li>
</ul>
</div></div></div></section><section data-id="8f4688e584a9bad3e84c61cdf98e3f4e"><div class="sl-block" data-block-type="text" data-name="text-022a8f" style="height: auto; width: 935px; left: 79px; top: 21px;" data-block-id="0f329d143326440a375b1dfa81c21ba3"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<h3 style="text-align:left"><strong><span style="color:#B22222">Antibiotic development timeline</span></strong></h3>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-d6211d" data-block-id="885ddefc55f3ffd051b4fae7580d459e" style="width: 980.338px; height: 312.924px; left: 40px; top: 159.719px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="2500" data-natural-height="798" data-lazy-loaded="" data-src="global_antimicrobial_resistance/745292868babf38c5e9ea5c0cc0e8c13.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-1920d2" data-block-id="fcc80da60ee358bb728418b6f64e117e" style="height: auto; width: 600px; left: 40px; top: 537px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; color: rgb(136, 136, 136);">
<p style="text-align:left"><span style="font-size:0.5em"><span style="color:#000000">source: </span><a href="http://www.react.org" target="_blank"><span style="color:#000000">www.react.org</span></a></span></p>
</div></div></section><section data-id="f331144d7c67ba25452eb8d4407261d6"><div class="sl-block" data-block-type="text" data-name="text-022a8f" style="height: auto; width: 1014px; left: 38px; top: 39px;" data-block-id="87087b89abf38c27d1fbb8a15fd1fb64"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; font-size: 90%;">
<h3 style="text-align: left;"><strong><span style="color:#B22222">Increase in numbers of group 1,2, and 3 beta-lactamases</span></strong></h3>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-01bd49" data-block-id="edd5f96b22b32f5dacff7a10f2b03b50" style="width: 767.232px; height: 426.24px; left: 128.384px; top: 92.88px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="1746" data-natural-height="970" data-lazy-loaded="" data-src="global_antimicrobial_resistance/8b6b65771f22a4d760013d344a4161ec.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-bb72ff" data-block-id="cd930ba64ef54564a50a3b05ee0c9e75" style="height: auto; width: 616px; left: 237px; top: 510.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p style="text-align:left"><span style="font-size:0.5em"><span style="color:rgb(51, 51, 51); text-align:start">Bush, K. &amp; Jacoby, G. A.</span><span style="color:rgb(51, 51, 51); text-align:start"> </span><em>Antimicrobial Agents and Chemotherapy</em><span style="color:rgb(51, 51, 51); text-align:start"> </span><strong>54</strong><span style="color:rgb(51, 51, 51); text-align:start">, 969–976 (2010).</span></span></p>
</div></div></section><section data-id="b16c50766c9b9946b17839d97cfb9e1d"><div class="sl-block" data-block-type="text" style="width: 987px; left: 18.5px; top: 21px; height: auto;" data-block-id="82eb94dc4b0d82928b7e38b1d119e567">
    <div class="sl-block-content" data-placeholder-tag="h1" data-placeholder-text="Title Text" style="z-index: 10;">
        <h3 style="color:rgb(60, 66, 69); text-align:start"><span style="font-size:0.9em"><span style="color:#B22222"><strong>Global Research and Development Priorities for AMR</strong></span></span></h3>
    </div>
</div>
<div class="sl-block" data-block-type="table" data-name="table-a701f1" data-block-id="8b85de70c93f2277e39e2b650874939a" style="height: auto; min-width: 120px; width: 833px; left: 84.5px; top: 113px;">
    <div class="sl-block-content" style="z-index: 11; font-size: 50%;" data-table-rows="4" data-table-cols="2">
        <table>
            <tbody>
                <tr>
                    <th style="width: 211px;">Priority</th>
                    <th>Pathogens included</th>
                </tr>
                <tr>
                    <td style="width: 211px;"><strong>Critical</strong></td>
                    <td>
                        <em>Acinetobacter baumannii</em> (Carbapenem-resistant)<br>
                        <em>Pseudomonas aeruginosa</em> (Carbapenem-resistant)<br>
                        Enterbacterales (3rd generation cephalosporin, carbapenem-resistant)</td>
                </tr>
                <tr>
                    <td style="width: 211px;"><strong>High</strong></td>
                    <td>
                        <em>Enterococcus faecium</em>, vancomycin-resistant<br>
                        <em>Staphylococcus aureus</em>, methicillin-resistant, vancomycin intermediate and resistant<br>
                        <em>Helicobacter pylori</em>, clarithromycin-resistant<br>
                        <em>Campylobacter</em>, fluoroquinolone-resistant<br>
                        <em>Salmonella</em> spp., fluoroquinolone-resistant<br>
                        <em>Neisseria gonorrhoeae</em>, 3rd gen. cephalosporin-resistant, fluoroquinolone-resistant</td>
                </tr>
                <tr>
                    <td style="width: 211px;"><strong>Medium</strong></td>
                    <td>
                        <em>Streptococcus pneumoniae</em>, penicillin-non-susceptible<br>
                        <em>Haemophilus influenzae</em>, ampicillin-resistant<br>
                        <em>Shigella</em> spp., fluoroquinolone-resistant</td>
                </tr>
            </tbody>
        </table>
    </div>
</div>
<div class="sl-block" data-block-type="text" data-name="text-ab144e" data-block-id="fff0db97e0ba02342e00ddc59c96b1ce" style="height: auto; width: 919px; left: 87px; top: 419.5px;">
    <div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; line-height: 0.845; text-align: left;" data-has-line-height="">
        <p><span style="font-size:0.5em">This table does not include <em>Mycobacterium tuberculosis</em>, which was already recognized as a global health priority pathogen</span></p>
    </div>
</div>
<div class="sl-block" data-block-type="text" data-name="text-55ccad" data-block-id="53dace054028b1c6a0ec61040aa8d253" style="height: auto; width: 341px; left: 87px; top: 529px;">
    <div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 13; text-align: left; color: rgb(0, 0, 0);">
        <p><span style="font-size:0.5em">Source:<a href="https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf" target="_blank">W</a><a href="http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf" target="_blank">orld Health Organization</a></span></p>
    </div>
</div></section><section data-id="5bab2af93c9479729d7a9477ca7a0f08">
<div class="sl-block" data-block-type="text" style="width: 938px; left: 79px; top: 21px; height: auto;" data-block-id="3ec5ac034923ad8df429c110a7ae2851" data-name="text-d4745e">
    <div class="sl-block-content" data-placeholder-tag="h1" data-placeholder-text="Title Text" style="z-index: 10;" dir="ui"><h3 style="color:rgb(60, 66, 69); text-align:start"><span style="font-size:0.9em"><span style="color:#B22222"><strong>WHO Clinical Antibiotic Pipeline Report</strong></span></span></h3></div>
</div>
<div class="sl-block" data-block-type="text" data-name="text-7c8287" data-block-id="26828eb71d0fd132ca45eb6a8264649e" style="height: auto; width: 277px; left: 159.55px; top: 537px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><a href="https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens-Oct-2018#what-you-see" target="_blank"><span style="font-size:0.5em">www.WHO.int</span></a></p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-b4371b" data-block-id="6f77386e366ab09106352ef5f94f7d9c" style="height: auto; width: 496px; left: 512px; top: 116px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; line-height: 1.04; font-size: 75%;" data-has-line-height="">
<ul>
	<li class="fragment" data-fragment-index="0">
	<p><span style="font-size:0.7em">The clinical pipeline remains insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance.</span></p>
	</li>
	<li class="fragment" data-fragment-index="1">
	<p><span style="font-size:0.7em">It is primarily driven by small- or medium-sized enterprises (SMEs), with large pharmaceutical companies continuing to exit the field.</span></p>
	</li>
	<li class="fragment" data-fragment-index="2">
	<p><span style="font-size:0.7em">Eight new antibacterial agents have been approved since 1 July 2017, but overall, they have limited clinical benefits.</span></p>
	</li>
	<li class="fragment" data-fragment-index="3">
	<p><span style="font-size:0.7em">One new anti-tuberculosis (anti-TB) agent, pretomanid, developed by a not-for-profit organization, has been approved for use within a set drug-combination treatment for MDR TB.</span></p>
	</li>
	<li class="fragment" data-fragment-index="4">
	<p><span style="font-size:0.7em">The current clinical pipeline contains 50 antibiotics and combinations (with a new therapeutic entity) and 10 biologicals, of which 32 antibiotics are active against the WHO priority pathogens</span></p>
	</li>
</ul>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-b357b3" data-block-id="a37d03a925d9fb8f63e80ea59a386a75" style="width: 303.104px; height: 426.24px; left: 159.55px; top: 97.88px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 13; filter: drop-shadow(rgba(0, 0, 0, 0.5) 0px 0px 5px);"><div class="sl-block-content" style="z-index: 13;"><img style="" data-natural-width="960" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/9a3f1e663acdd70e38db83f6e7b40269.png"></div></div></div></section><section data-id="118fdd342e2f492bc0fd73d383917a82"><div class="sl-block" data-block-type="text" style="width: 776px; left: 143.25px; top: 237px; height: auto;" data-block-id="2de9d01a8cd7a9ecafee6dc0504bba15" data-name="text-3c0a6d">
    <div class="sl-block-content" data-placeholder-tag="h1" data-placeholder-text="Title Text" style="z-index: 11; text-align: center;">
<h3 style="color: rgb(60, 66, 69);"><span style="font-size:0.9em"><span style="color:#B22222"><strong>Why is antibiotic discovery faltering?</strong></span></span></h3>
</div>
</div>
<div class="sl-block" data-block-type="image" data-name="image-123268" data-block-id="f45ea5ed418bb71cb275f2c1c0b2fe5e" style="width: 847.5px; height: 565px; left: 103.5px; top: 5.5px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 10; opacity: 0.25;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="2025" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/bc66786708e0009bc4fa4fa77dfb3af3.jpg"></div></div></div></section><section data-id="06127301b55b7700e86beea9aaafa455"><div class="sl-block" data-block-type="text" style="width: 920px; left: 0px; top: 56px; height: auto;" data-block-id="0a5a1ad54326e9b43b2547b09eeb6ec5"><div class="sl-block-content" data-placeholder-tag="h2" data-placeholder-text="Title Text" style="z-index: 10;">
<h3><font color="#b22222"><strong>The challenges of antibiotic discovery</strong></font></h3>
</div></div>
<div class="sl-block" data-block-type="text" style="width: 913px; left: 67px; top: 151.5px; height: auto;" data-block-id="175dc37a6c2cb56927150dc1c7ae6172"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; line-height: 1.43;" data-has-line-height="">
<ul>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="0">
	<p>Ideally hit multiple targets in bacterial species (to avoid rapid resistance development) ...<em>but not human targets</em></p>
	</li>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="1">
	<p>Must be safe...drugs are <em>administered grams not mg or mcg</em></p>
	</li>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="2">
	<p>Must penetrate multiple body sites</p>
	</li>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="3">
	<p>Must be effective against future forms of resistance (i.e. predict 10 years into the future)</p>
	</li>
</ul>
</div></div></section><section data-id="7dfb8b2a23663d80c4d9eb3a8a76d750"><div class="sl-block" data-block-type="text" data-name="text-6db258" data-block-id="23994e195a330437c18a89f5a2f6002c" style="height: auto; width: 1053px; left: 0px; top: 6px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; color: rgb(152, 0, 0); line-height: 0.975; font-size: 85%;" data-has-line-height="">
<h3><strong><span style="font-size:0.9em">Natural product screening:</span></strong></h3>

<h3><span style="font-size:0.7em">The "golden age" of antibiotic discovery before 1965 from soil streptomycetes and fungi</span></h3>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-7f2c72" data-block-id="af2071f211a02e8dc145f78ddf4ee042" style="width: 506.358px; height: 424.36px; left: 110.612px; top: 90px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="1198" data-natural-height="1004" data-lazy-loaded="" data-src="global_antimicrobial_resistance/c0296ebdaf1c906f25686f920746ba94.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-8f2bf8" data-block-id="272d5fc4c3f595898c89a818641a5ea3" style="height: auto; width: 600px; left: 212px; top: 492.12px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; color: rgb(0, 0, 0);">
<p><span style="font-size:0.5em">Penicillin culture flasks, 1942. Photo: <span style="text-align:left">James Jarche</span></span></p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-cad614" data-block-id="7646b39e6f98d6160b2647a622c94cdb" style="width: 301.638px; height: 393.24px; left: 616.97px; top: 98.88px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 13;"><img style="" data-natural-width="652" data-natural-height="850" data-lazy-loaded="" data-src="global_antimicrobial_resistance/a5b9fdd1fdc8dadd8de3205ca459e697.png"></div></div></section><section data-id="cd9aaca2435ca92dc6866047613c6b9f"><div class="sl-block" data-block-type="text" data-name="text-6db258" style="height: auto; width: 1053px; left: 0px; top: 16.5px;" data-block-id="42050738e8ed6215ed2db905cc8a8bce"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; color: rgb(152, 0, 0);">
<h3><strong>1970s to 1990s- modified chemistry</strong></h3>

<h3><strong> to overcome resistance</strong></h3>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-cca12c" data-block-id="3e6184624c5ed76fea64b1ef3e968d2e" style="height: auto; width: 921px; left: 59px; top: 415px;"><div class="sl-block-content fragment" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;" data-fragment-index="0">
<p><span style="color:#696969">Since 1970, the only indisputably new antibiotic classes to reach the market are: the oxazolidinones (discovered 1978, launched 2000) and lipopeptides (discovered 1986, launched 2003)</span></p>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 822px; left: 9.367px; top: 175.5px;" data-block-id="d906489711f824bc34476518296ce0fe" data-name="text-e7ff72"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p>Penicillins → cephalosporins, carbapenems</p>

<p>nalidixic acid <span style="color:rgb(0, 0, 0)">→ fluoroquinolones</span></p>

<p><span style="color:rgb(0, 0, 0)">kanamycin </span> <span style="color:rgb(0, 0, 0)">→ </span>amakacin</p>

<p>glycyclines <span style="color:rgb(0, 0, 0)">→ tetracyclines</span></p>

<p> </p>
</div></div>
<div class="sl-block sl-block-group" data-block-type="group" data-name="group-c07e95" data-block-id="599455f0a193e322ce82af511e82a1a4" style="height: auto;"><div class="sl-block-content sl-block-group-content" style="transform-origin: 869px 270.793px; z-index: 13;">
<div class="sl-block" data-block-type="drawing" data-name="drawing-dbe8ad" data-block-id="9b1c37ce8fe4aedef7710abdb12e82a4" style="width: 60.2434px; height: 163.157px; left: 730.562px; top: 189.215px;"><div class="sl-block-content fragment" data-points="957.34 481.58,961.65 481.68,967.54 481.29,974.08 480.58,979.29 479.75,981.78 479.15,983.71 478.18,985.55 476.61,987.68 474.42,989.17 472.57,991.06 469.92,992.17 466.66,992.66 463.78,993.26 460.27,993.59 456.37,993.59 453.97,993.59 451.67,993.44 448.67,993.44 445.88,993.28 443.1,993.28 440.86,992.84 437.28,992.46 433.87,992.25 431.61,992.25 429.24,992.36 426.56,992.48 423.12,992.72 420.37,993.48 417.84,994.46 415.35,995.53 413.05,996.57 411.25,998.42 410.26,1001.06 409.28,1003.28 408.46,1005.59 407.55,1007.47 406.67,1010.09 405.91,1008.05 405.35,1005.83 404.81,1003.82 404.38,1001.25 401.41,999.37 398.87,998.76 395.51,998.31 392.85,998.19 390.79,998.05 387.42,997.91 384.47,997.79 380.5,997.89 377.91,998.41 375.1,998.93 371.83,999.52 368.33,999.88 366.24,1000.75 364.11,1001.51 362.21,1002.19 360.21,1002.82 358.11,1003.06 355.7,1003.3 352.99,1003.43 350.53,1003.43 348.24,1003.32 345.13,1002.73 342.81,1000.6 339.96,999.76 338.09,997.23 335.96,994.12 333.54,992.55 332.02,990.52 330.42,988.34 329.56,984.62 327.94,980.77 326.38,975.78 326,970.31 326,968.07 326" data-timestamp="1640102920558" style="z-index: 14;" data-fragment-index="2"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="none" width="100%" height="100%" viewbox="953.6244506835938 322.2137451171875 60.243408203125 163.15664672851562"><path fill="#000" d="M 958.3698710042124 477.8384195277879 Q 958.37 477.84 960.45 477.82 962.53 477.79 965.31 477.63 968.08 477.46 971.09 477.16 974.09 476.87 976.64 476.26 979.2 475.65 981.61 473.99 984.03 472.33 985.98 469.16 987.93 465.98 988.58 462.3 989.23 458.61 989.32 455.44 989.42 452.28 989.31 448.66 989.21 445.04 989.04 442.33 988.88 439.62 988.57 436.57 988.26 433.53 988.16 430.81 988.06 428.09 988.27 424.97 988.49 421.86 989.15 418.79 989.82 415.72 991.2 413.06 992.58 410.4 994.93 408.3 997.27 406.2 1002.6 404.13 1007.92 402.07 1009.26 401.91 1010.59 401.76 1011.76 402.42 1012.93 403.08 1013.49 404.3 1014.05 405.53 1013.78 406.84 1013.51 408.16 1012.66 408.33 1011.8 408.49 1008.2 408.4 1004.59 408.31 1001.05 405.56 997.51 402.81 996.01 399.2 994.51 395.59 994.18 392.72 993.85 389.85 993.75 386.61 993.65 383.37 993.77 379.96 993.89 376.54 994.4 373.36 994.91 370.17 995.5 367.39 996.09 364.6 996.91 362.08 997.74 359.56 998.27 356.66 998.81 353.77 998.72 350.44 998.64 347.1 997.31 344.25 995.97 341.4 993.32 338.86 990.66 336.32 987.89 334.58 985.13 332.84 981.36 331.6 977.59 330.37 974.51 330.21 971.44 330.05 969.52 328.32 967.6 326.6 968.99 324.43 970.39 322.27 972.75 323.31 975.11 324.35 974.45 326.85 973.79 329.34 971.23 329.08 968.66 328.82 968.52 326.24 968.37 323.66 971.92 322.84 975.47 322.01 978.42 322.28 981.37 322.54 984.94 323.77 988.5 325 991.44 326.64 994.38 328.28 996.82 330.18 999.27 332.08 1001.35 334.39 1003.43 336.71 1005.14 340.12 1006.85 343.54 1007.29 346.62 1007.72 349.71 1007.57 352.46 1007.42 355.21 1006.94 357.89 1006.45 360.57 1005.5 363.26 1004.54 365.95 1003.91 368.74 1003.29 371.54 1002.79 375.23 1002.29 378.93 1002.29 382.46 1002.28 386 1002.57 389.58 1002.87 393.16 1003.86 396.09 1004.84 399.03 1007.07 400.22 1009.3 401.41 1009.95 401.59 1010.59 401.76 1011.76 402.42 1012.93 403.08 1013.49 404.3 1014.05 405.53 1013.78 406.84 1013.51 408.16 1012.52 409.07 1011.53 409.98 1006.06 412.25 1000.58 414.52 999.04 417.08 997.51 419.63 997.1 422.61 996.68 425.6 996.67 428.89 996.67 432.19 996.99 435.76 997.3 439.34 997.45 442.16 997.6 444.98 997.65 447.78 997.71 450.57 997.67 453.28 997.63 455.98 997.23 459.52 996.83 463.07 995.77 466.89 994.7 470.71 992.92 473.49 991.14 476.28 988.72 478.49 986.3 480.7 983.43 481.87 980.55 483.04 977.74 483.56 974.92 484.08 971.76 484.48 968.6 484.88 965.55 485.13 962.51 485.38 960.35 485.37 958.2 485.37 957.72 485.35 957.25 485.34 956.67 485.24 956.09 485.13 955.58 484.85 955.06 484.57 954.65 484.15 954.24 483.72 953.99 483.19 953.73 482.66 953.66 482.08 953.58 481.49 953.68 480.91 953.79 480.33 954.07 479.82 954.35 479.3 954.77 478.89 955.2 478.48 955.73 478.23 956.26 477.97 956.84 477.9 957.43 477.82 957.9 477.83 Z"></path></svg></div></div>
<div class="sl-block" data-block-type="text" data-name="text-192dc9" data-block-id="84b67db6f7045dcec2336113bbc25ef8" style="height: auto; width: 230px; left: 777.438px; top: 203.293px;"><div class="sl-block-content fragment" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 15; line-height: 0.975;" data-has-line-height="" data-fragment-index="1">
<p><em><strong>class</strong></em></p>

<p><em><strong>resistance</strong></em></p>

<p><em><strong>mechanisms</strong></em></p>

<p><em><strong>develop</strong></em></p>
</div></div>
</div></div></section><section data-id="0dd3a79dccc11de4e54041198bb97544"><div class="sl-block" data-block-type="text" data-name="text-6db258" style="height: auto; width: 882px; left: 112px; top: 0px;" data-block-id="7f0c03ac73e2e5649e568ac0e0b7f8ac"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; color: rgb(152, 0, 0); line-height: 1.17;" data-has-line-height="">
<h3><strong>1990s...</strong></h3>

<p><strong>Genomics-driven antibiotic target identification</strong></p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-a794ae" data-block-id="8f05c6e16a4a27b391fa60a01058f140" style="width: 890.336px; height: 497px; left: 86.921px; top: 79px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="left: 0px; top: 0px; width: 898px; height: 628px;" data-natural-width="1929" data-natural-height="1350" data-lazy-loaded="" data-crop-x="0" data-crop-y="0" data-crop-width="0.99179" data-crop-height="0.79108" data-src="global_antimicrobial_resistance/bae4dda372b0e8320f2bccafab18ba3c.png"></div></div></section><section data-id="1b78331a71e86162224ec6609f6a18c9"><div class="sl-block" data-block-type="text" data-name="text-6db258" style="height: auto; width: 908.942px; left: 39.058px; top: 13px;" data-block-id="b86f45f0d04d0f77c908f528c21ed138"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; color: rgb(152, 0, 0); line-height: 1.105;" data-has-line-height="">
<h3><strong>But few candidate antibiotics found</strong></h3>

<p>67 high-throughput screens, each of 260,000 –530,000...compounds tested....<strong>no drugs developed</strong></p>

<p> </p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-3a5fe9" data-block-id="cc5a8acbfce516bd5a9af8d18f158dc3" style="width: 553px; height: 345.917px; left: 14.0575px; top: 182.76px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="1896" data-natural-height="1186" data-lazy-loaded="" data-src="global_antimicrobial_resistance/5bbc42cb2c6a8ff0fde4efb3efaaff8f.png"></div></div>

<div class="sl-block" data-block-type="text" data-name="text-e315a2" data-block-id="6c47a6305ddc930530db34daa33fe4ea" style="height: auto; width: 600px; left: 212px; top: 538px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; line-height: 0.975;" data-has-line-height="">
<p><span style="font-size:0.5em">Payne, D. J.,et al.  <em>Nature reviews. Drug discovery </em><strong>6</strong>, 29–40 (2007). </span></p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-c5fd52" data-block-id="07b2e5c1d9c12368b1bc9e24f390b64d" style="width: 751.049px; height: 426.24px; left: 136.476px; top: 74.88px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 13; filter: drop-shadow(rgba(0, 0, 0, 0.5) 0px 0px 5px);"><div class="sl-block-content fragment" style="z-index: 13; border-style: solid; border-width: 1px;" data-fragment-index="0"><img style="" data-natural-width="1318" data-natural-height="748" data-lazy-loaded="" data-src="global_antimicrobial_resistance/0c429aaad59d3f36ed7606db1ef39507.png"></div></div></div></section><section data-id="11b158827daba740d8b268e17ff21d8d"><div class="sl-block" data-block-type="text" style="width: 860px; left: 82px; top: 219px; height: auto;" data-block-id="8328720427c78f900edf3ffb0b9e9a58"><div class="sl-block-content" data-placeholder-tag="h1" data-placeholder-text="Title Text" style="z-index: 11; color: rgb(152, 0, 0);">
<h3>Regulatory requirements</h3>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-92b1f1" data-block-id="c1aa69d74d2dde12de9bbec09e1de075" style="width: 980.036px; height: 546.174px; left: 31px; top: 14.913px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 10; opacity: 0.25;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="1274" data-natural-height="710" data-lazy-loaded="" data-src="global_antimicrobial_resistance/e8ef73862d4984e9f4f2a551839f9fd9.png"></div></div></div></section><section data-id="164ed0c905473d18ea9c49dd176ac432"><div class="sl-block" data-block-type="image" data-name="image-420c1c" data-block-id="aa41d98ec531a34a34e0bdca8319b7d1" style="width: 450.016px; height: 95.458px; left: 61.984px; top: 222.271px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="990" data-natural-height="210" data-lazy-loaded="" data-src="global_antimicrobial_resistance/55b95be64f719a050c8c9dd2d92c7f7f.png"></div></div>
<div class="sl-block" data-block-type="image" data-name="image-aff28a" data-block-id="0da00d57dd15732112d6daef378f5157" style="width: 295.538px; height: 166.24px; left: 61.984px; top: 26.76px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="1920" data-natural-height="1080" data-lazy-loaded="" data-src="global_antimicrobial_resistance/430523b3f94979a96be9fb82375e8c24.jpeg"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-01d2b0" data-block-id="3463deca013d7420b29ec0a704c49b8f" style="height: auto; width: 424px; left: 524px; top: 54.88px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; text-align: left;">
<p><strong>United States Food and Drug Administration</strong></p>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 424px; left: 524px; top: 250.5px;" data-block-id="da85a472b4c48848a2bf7b6bd233b5f2" data-name="text-ee8cee"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 13; text-align: left;">
<p><strong>EMA</strong></p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-799d19" data-block-id="3c8a933f3bb4feb58089f0a778420024" style="width: 207.56px; height: 141.12px; left: 79px; top: 351.169px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 14;"><img style="" data-natural-width="806" data-natural-height="548" data-lazy-loaded="" data-src="global_antimicrobial_resistance/d4b4dfa24e906803a448e5ba1497e96a.png"></div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 424px; left: 524px; top: 421.729px;" data-block-id="a8c04339a34920e98e67f4b2652385a8" data-name="text-bd1c9f"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 15; text-align: left;">
<p><strong>African Medicines Agency</strong></p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-63942c" data-block-id="41f5ca75e99aadfdc15eb64810843361" style="height: auto; width: 799px; left: 137.432px; top: 515.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 16; line-height: 0.91; text-align: left;" data-has-line-height="">
<p><span style="font-size:0.7em">Many LMICs have their own processes for drug registration and approval</span></p>
</div></div></section><section data-id="8abf2306c8708ff73f758c53bcabf79b"><div class="sl-block" data-block-type="image" data-name="image-d58f0d" data-block-id="836ee753040185f0fff68e8a98e2cbd1" style="width: 688.81px; height: 460.56px; left: 180.19px; top: 80.44px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="left: 0px; top: 0px; width: 703px; height: 581px;" data-natural-width="1634" data-natural-height="1350" data-crop-x="0" data-crop-y="0" data-crop-width="0.979592" data-crop-height="0.792776" data-lazy-loaded="" data-src="global_antimicrobial_resistance/b26dd79e4952997a392d87819ebc2300.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-6db258" style="height: auto; width: 908.942px; left: 39.058px; top: 0px;" data-block-id="f0fb707be9f9f050bd60e6d91a0cdb5e"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; color: rgb(152, 0, 0); line-height: 1.105;" data-has-line-height="">
<h3><span style="font-size:0.9em">Antibiotic approval process and expected costs</span></h3>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-a37ac4" data-block-id="084b0c21a3dc94e55a941c4e4abd6154" style="height: auto; width: 296px; left: 364px; top: 49px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; line-height: 0.975; font-size: 80%;" data-has-line-height="">
<p>1-1.5 billion US dollars</p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-9fbc7c" data-block-id="de4a40fe110d7b8c06d1f09475291bab" style="height: auto; width: 676px; left: 203.458px; top: 551px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 13; line-height: 0.585;" data-has-line-height="">
<p><span style="font-size:0.5em">Wouters et al.</span> <span style="font-size:0.5em"><em>JAMA </em>323, 844–853 (2020). </span></p>
</div></div></section><section data-id="2f5a8dc8834bccb93215eefb8bca7616"><div class="sl-block" data-block-type="text" data-name="text-0c62f5" data-block-id="519babb9d04c4c6308828b8ce15a7c8b" style="height: auto; width: 1006px; left: 0px; top: 10.4089px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;" dir="ui">
<p><span style="color:#B22222"><strong>Phase III non-inferiority trial:</strong></span></p>

<p><span style="color:#B22222">The paradox of antibiotics</span></p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-45ae54" data-block-id="78b7fac59bcba69a414ad0550901ef9f" style="height: auto; width: 852.5px; left: 53px; top: 123px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<ul>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="0" style="font-size:21px; text-align:left">
<span style="font-size:1.0em"><strong>Medical Priority:  New drugs for bad bugs</strong></span>
	<ul>
		<li style="font-size:21px; text-align:left"><span style="font-size:1.0em">The superiority of a NEW antiboitics is easily shown in the lab on the basis of MIC testing or in animal models of infection</span></li>
	</ul>
	</li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="1" style="font-size:21px; text-align:left">
	<p><span style="font-size:1.0em"><strong>But asking for clinical data leads to a problem. trials must (usually) be designed to avoid superiority</strong></span></p>

	<ul>
		<li style="font-size:21px; text-align:left">
		<p><span style="font-size:1.0em">Instead, we must use <em>non-inferiority designs</em> showing similar activity relative to another <em>active agent </em></span></p>
		</li>
		<li style="font-size:21px; text-align:left">
		<p><span style="font-size:1.0em">Example: Limb-threatening infection due to MRSA....It is not ethical to randomize to methicillin vs. NEW Antibiotic, must instead compare vancomycin vs. NEW Antibiotic ​</span></p>
		</li>
	</ul>
	</li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="2" style="font-size:21px; text-align:left">
	<p style="font-size:21px; text-align:left"><span style="font-size:1.0em"><strong>Patients cannot be enrolled if known or likely resistant to New Antibiotioc or comparator</strong></span></p>
	</li>
</ul>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-a3a69d" data-block-id="39c7a5ce5ea09658e1be1760e7889573" style="height: auto; width: 600px; left: 286px; top: 528.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p><span style="font-size:0.5em">Slide: John Rex, M.D.</span></p>
</div></div></section><section data-id="2db82b82d034612ddba3f931b1a54113">












<div class="sl-block" data-block-type="line" data-name="line-5e8501" data-block-id="d31fb1f66d34333e1011a344b4105b38" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 522px; top: 33.5px;"><div class="sl-block-content" data-line-x1="0" data-line-y1="447" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 10;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="447" viewbox="0 0 1 447"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0" y1="447" x2="0" y2="0"></line><line class="line-element" stroke="#000000" stroke-width="2" x1="0" y1="447" x2="0" y2="0"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 107px; top: 480.5px;" data-block-id="786cb72f5f53abee91c3c1fd71bdc3ee" data-name="line-4e24e1"><div class="sl-block-content" data-line-x1="0" data-line-y1="0" data-line-x2="841" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 11;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="841" height="1" viewbox="0 0 841 1"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0" y1="0" x2="841" y2="0"></line><line class="line-element" stroke="#000000" stroke-width="2" x1="0" y1="0" x2="841" y2="0"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 411px; top: 113px;" data-block-id="1d1600e396d0d62dd33343f607046344" data-name="line-9776b3"><div class="sl-block-content" data-line-x1="0" data-line-y1="367.5" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 12;" data-line-width="4px" data-line-style="dashed"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="367.5" viewbox="0 0 1 367.5"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0" y1="367.5" x2="0" y2="0"></line><line class="line-element" stroke="#000000" stroke-width="4" stroke-dasharray="11.850000000000001 11.850000000000001" x1="0" y1="367.5" x2="0" y2="0"></line></svg></div></div>
<div class="sl-block" data-block-type="text" data-name="text-69effd" data-block-id="903e08c67d4c110c4e4551526d0e2850" style="height: auto; width: 399.989px; left: 54.001px; top: 14px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 13; color: rgb(152, 0, 0);">
<p><span style="font-size:0.9em"><strong>Favors active control drug </strong></span></p>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 221px; left: 587px; top: 14px;" data-block-id="515a41b5a77e93b0c53523d3c12b2464" data-name="text-6fab39"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 14; color: rgb(152, 0, 0);">
<p><span style="font-size:0.9em"><strong>Favors test drug</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 288.989px; left: 20.5065px; top: 63px;" data-block-id="a9af58767a8c99f8539baff6e57fc993" data-name="text-b00af0"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 15;">
<p><strong><span style="font-size:0.7em">Non-inferiority Margin</span></strong></p>

<p><span style="font-size:0.5em"><strong>(varies by indication and trial design)</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 19.211px; left: 517.011px; top: 497.5px;" data-block-id="dbd8c569300184f3de5256a59ceccad5" data-name="text-98480c"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 47; line-height: 0.65; text-align: left;" data-has-line-height="">
<p><span style="font-size:21px"><strong>0</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 633.989px; left: 329.728px; top: 541px;" data-block-id="9542c41e596c3839a9ce73589e678cdb" data-name="text-d1c250"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 48; line-height: 0.65; text-align: left;" data-has-line-height="">
<p><span style="font-size:21px"><strong>Treatment difference (Test drug-control)</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 77.5px; left: 370.989px; top: 66px;" data-block-id="1956ff21b1dcb2c4aab3c30a7b8dbed4" data-name="text-a72a7c"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 49;">
<p><span style="font-size:1.0em"><strong>Δ</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="shape" data-name="shape-fb647f" data-block-id="c5ed4b10068fc8a3f01c33af6e384bab" style="width: 46.0005px; height: 33.5px; left: 297.718px; top: 71.5px;"><div class="sl-block-content" data-shape-type="arrow-right" data-shape-fill-color="#000000" data-shape-stretch="true" style="z-index: 50;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 46 34"><polygon points="0,10.049999999999999 23.00025,10.049999999999999 23.00025,0 46.0005,16.75 23.00025,33.5 23.00025,23.45 0,23.45" class="shape-element" fill="#000000"></polygon></svg></div></div>

<div class="sl-block sl-block-group" data-block-type="group" data-name="group-ab6d7e" data-block-id="c9000ff6fef98a74f3cff6c43b8295e7" style="height: auto;"><div class="sl-block-content sl-block-group-content" style="transform-origin: 572.5px 389.25px; z-index: 26;">
<div class="sl-block sl-block-group" data-block-type="group" data-block-id="7037f6dc86d898cb1ee26fd6ed7faa0c" data-name="group-78ee78"><div class="sl-block-content sl-block-group-content" style="transform-origin: 463.309px 391px; z-index: 27;">
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 418.503px; top: 391px;" data-origin-id="d3b30475417d0d37846a0c31e6e0401b" data-block-id="4e57d2bdd2fa00549567de6cecf12463" data-name="line-08f50d"><div class="sl-block-content" data-line-x1="0" data-line-y1="0" data-line-x2="83.97789532863658" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 28;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="83.97789532863658" height="1" viewbox="0 0 83.97789532863658 1"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="0.5" x2="84.47789532863658" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="0.5" x2="84.47789532863658" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 419.58px; top: 370.5px;" data-origin-id="25c2b09c461fae09ee948f04ead225d2" data-block-id="7b102cd35680c5b888978368e33d4da1" data-name="line-36e3ea"><div class="sl-block-content" data-line-x1="0" data-line-y1="41" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 29;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="41" viewbox="0 0 1 41"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 502.121px; top: 370.5px;" data-origin-id="785c6b34f0dd67cfff2ae238cfe3a57e" data-block-id="42bd6e0d894a57299c87df5c8ab0b32a" data-name="line-762034"><div class="sl-block-content" data-line-x1="0" data-line-y1="41" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 30;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="41" viewbox="0 0 1 41"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line></svg></div></div>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 193.989px; left: 532.508px; top: 367px;" data-block-id="1985c9a5e34069f8d16f85f570795353" data-name="text-0da287"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 31; line-height: 0.65; text-align: left;" data-has-line-height="">
<p><span style="font-size:21px"><strong>Non-inferior and inferior</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="shape" style="width: 29px; height: 28px; left: 445.992px; top: 377px;" data-block-id="44c51a96a74739fc6ad0afa6174e39d4" data-name="shape-d5baba"><div class="sl-block-content" data-shape-type="circle" data-shape-fill-color="#000000" data-shape-stretch="true" style="z-index: 32;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 29 28"><ellipse rx="14.5" ry="14" cx="14.5" cy="14" class="shape-element" fill="#000000"></ellipse></svg></div></div>
</div></div>
<div class="sl-block sl-block-group" data-block-type="group" data-name="group-0a2a19" data-block-id="7bc424bcb91aadafb041a99f559d3a2e" style="height: auto;"><div class="sl-block-content sl-block-group-content" style="transform-origin: 229.785px 431.5px; z-index: 40;">
<div class="sl-block sl-block-group" data-block-type="group" data-block-id="469bbc3b733e5a59b5e9e1f228f90d1b" data-name="group-7b2568"><div class="sl-block-content sl-block-group-content" style="transform-origin: 335.486px 431.5px; z-index: 41;">
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 271.598px; top: 430.5px;" data-origin-id="4e57d2bdd2fa00549567de6cecf12463" data-block-id="50c931417108397e0b7ede9af7504840" data-name="line-d8f707"><div class="sl-block-content" data-line-x1="0" data-line-y1="0" data-line-x2="108.43586952096189" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 42;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="108.43586952096189" height="1" viewbox="0 0 108.43586952096189 1"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="0.5" x2="108.93586952096189" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="0.5" x2="108.93586952096189" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 272.989px; top: 410px;" data-origin-id="7b102cd35680c5b888978368e33d4da1" data-block-id="4e5eed473eeaaa48e4be151f9d8ab709" data-name="line-4b5df3"><div class="sl-block-content" data-line-x1="0" data-line-y1="41" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 43;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="41" viewbox="0 0 1 41"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 379.569px; top: 410px;" data-origin-id="42bd6e0d894a57299c87df5c8ab0b32a" data-block-id="9bfce8d58f5161e51585c3a4bb978c07" data-name="line-56eb00"><div class="sl-block-content" data-line-x1="0" data-line-y1="41" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 44;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="41" viewbox="0 0 1 41"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line></svg></div></div>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 193.989px; left: 79px; top: 413px;" data-block-id="a41010cceb80719506416a45419c003d" data-name="text-deff11"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 45; line-height: 0.65; text-align: left;" data-has-line-height="">
<p><span style="font-size:21px"><strong>Non-inferior and not inferior</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="shape" style="width: 29px; height: 28px; left: 311.316px; top: 416.5px;" data-block-id="c415c04db07714d422eccba55f9a499d" data-name="shape-0fad19"><div class="sl-block-content" data-shape-type="circle" data-shape-fill-color="#000000" data-shape-stretch="true" style="z-index: 46;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 29 28"><ellipse rx="14.5" ry="14" cx="14.5" cy="14" class="shape-element" fill="#000000"></ellipse></svg></div></div>
</div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 39.979px; left: 395px; top: 496.5px;" data-block-id="61329637b762c237a6f5ca263a6e004d" data-name="text-0d523b"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 51; line-height: 0.65; text-align: left;" data-has-line-height="">
<p><span style="font-size:21px"><strong>-10</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="shape" style="width: 46.0005px; height: 33.5px; left: 527.5px; top: 21.5px;" data-block-id="1d2bcd01599d9666b1c9a71aec39eee9" data-name="shape-574c0f"><div class="sl-block-content" data-shape-type="arrow-right" data-shape-fill-color="rgb(152, 0, 0)" data-shape-stretch="true" style="z-index: 52;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 46 34"><polygon points="0,10.049999999999999 23.00025,10.049999999999999 23.00025,0 46.0005,16.75 23.00025,33.5 23.00025,23.45 0,23.45" class="shape-element" fill="rgb(152, 0, 0)"></polygon></svg></div></div>
<div class="sl-block" data-block-type="shape" style="width: 46.0005px; height: 33.5px; left: 469px; top: 21.5px;" data-block-id="7a73332c7c39050f2dce92ce8e232944" data-name="shape-7b1073"><div class="sl-block-content" data-shape-type="arrow-left" data-shape-fill-color="rgb(152, 0, 0)" data-shape-stretch="true" style="z-index: 53;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 46 34"><polygon points="46.0005,10.049999999999999 23.00025,10.049999999999999 23.00025,0 0,16.75 23.00025,33.5 23.00025,23.45 46.0005,23.45 46.0005,10.049999999999999" class="shape-element" fill="rgb(152, 0, 0)"></polygon></svg></div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 197.989px; left: 669.01px; top: 204.5px;" data-block-id="3618b7c23ce5ddf62eb7e4a2029705b7" data-name="text-c4aeff"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 24; line-height: 0.325; text-align: left;" data-has-line-height="">
<p><strong><span style="font-size:0.7em">Non-inferior and</span></strong></p>

<p><strong><span style="font-size:0.7em">not superior</span></strong></p>
</div></div>
<div class="sl-block" data-block-type="shape" style="width: 29px; height: 28px; left: 535.005px; top: 204.5px;" data-block-id="39982c0f97a0b7d7d2b750701adbdf23" data-name="shape-68df28"><div class="sl-block-content" data-shape-type="circle" data-shape-fill-color="#000000" data-shape-stretch="true" style="z-index: 25;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 29 28"><ellipse rx="14.5" ry="14" cx="14.5" cy="14" class="shape-element" fill="#000000"></ellipse></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 441px; top: 218.5px;" data-block-id="8dbf0da2f760c92f87e772254c07b8af" data-name="line-04367b"><div class="sl-block-content" data-line-x1="0" data-line-y1="0" data-line-x2="205.7221766536594" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 21;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="205.7221766536594" height="1" viewbox="0 0 205.7221766536594 1"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="0.5" x2="206.2221766536594" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="0.5" x2="206.2221766536594" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 441.638px; top: 198px;" data-block-id="c8ae15ee9885b32becb12b687985c6d4" data-name="line-e3832b"><div class="sl-block-content" data-line-x1="0" data-line-y1="41" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 22;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="41" viewbox="0 0 1 41"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 645.842px; top: 198px;" data-block-id="c974f283dbc4d7d02eee4d648c070398" data-name="line-6de87f"><div class="sl-block-content" data-line-x1="0" data-line-y1="41" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 23;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="41" viewbox="0 0 1 41"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 193.989px; left: 574.016px; top: 285.5px;" data-block-id="5b5d3d878ec9aba27c69d4311da0aea9" data-name="text-90c441"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 38; line-height: 0.65; text-align: left;" data-has-line-height="">
<p><span style="font-size:21px"><strong>Non-inferiority not shown</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="shape" style="width: 29px; height: 28px; left: 459.5px; top: 291.5px;" data-block-id="b4f6335cdd34ffa0e248597787bcab16" data-name="shape-913a4e"><div class="sl-block-content" data-shape-type="circle" data-shape-fill-color="#000000" data-shape-stretch="true" style="z-index: 39;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 29 28"><ellipse rx="14.5" ry="14" cx="14.5" cy="14" class="shape-element" fill="#000000"></ellipse></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 387px; top: 306px;" data-origin-id="8dbf0da2f760c92f87e772254c07b8af" data-block-id="d3b30475417d0d37846a0c31e6e0401b" data-name="line-0b903e"><div class="sl-block-content" data-line-x1="0" data-line-y1="0" data-line-x2="172.76668233535474" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 35;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="172.76668233535474" height="1" viewbox="0 0 172.76668233535474 1"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="0.5" x2="173.26668233535474" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="0.5" x2="173.26668233535474" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 388.215px; top: 285.5px;" data-origin-id="c8ae15ee9885b32becb12b687985c6d4" data-block-id="25c2b09c461fae09ee948f04ead225d2" data-name="line-9a872f"><div class="sl-block-content" data-line-x1="0" data-line-y1="41" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 36;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="41" viewbox="0 0 1 41"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="line" style="width: auto; height: auto; min-width: 0px; min-height: 0px; left: 559.027px; top: 285.5px;" data-origin-id="c974f283dbc4d7d02eee4d648c070398" data-block-id="785c6b34f0dd67cfff2ae238cfe3a57e" data-name="line-47ea91"><div class="sl-block-content" data-line-x1="0" data-line-y1="41" data-line-x2="0" data-line-y2="0" data-line-color="#000000" data-line-start-type="none" data-line-end-type="none" style="z-index: 37;" data-line-width="3px"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" preserveaspectratio="xMidYMid" width="1" height="41" viewbox="0 0 1 41"><line stroke="rgba(0,0,0,0)" stroke-width="15" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line><line class="line-element" stroke="#000000" stroke-width="3" x1="0.5" y1="41.5" x2="0.5" y2="0.5"></line></svg></div></div>
<div class="sl-block" data-block-type="shape" data-name="shape-240660" data-block-id="7e82257a0efb7cec24462f945b841f04" style="width: 29px; height: 28px; left: 572.5px; top: 120px;"><div class="sl-block-content" data-shape-type="circle" data-shape-fill-color="#000000" data-shape-stretch="true" style="z-index: 17;"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 29 28"><ellipse rx="14.5" ry="14" cx="14.5" cy="14" class="shape-element" fill="#000000"></ellipse></svg></div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 197.989px; left: 643px; top: 116px;" data-block-id="90c27106aa3aa2b9c5d38fb31ae027ca" data-name="text-dd22ed"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 18; line-height: 0.325; text-align: left;" data-has-line-height="">
<p><strong><span style="font-size:0.7em">Non-inferior and</span></strong></p>

<p><strong><span style="font-size:0.7em">superior</span></strong></p>
</div></div></section><section data-id="b2d855fcd707db3c19e16ab3c85a81c0"><div class="sl-block" data-block-type="image" data-name="image-d58f0d" style="width: 688.81px; height: 460.56px; left: 0px; top: 61px; min-width: 1px; min-height: 1px;" data-block-id="50652c125d69e3839e0da72582e75aa6"><div class="sl-block-content" style="z-index: 10;"><img style="left: 0px; top: 0px; width: 703px; height: 581px;" data-natural-width="1634" data-natural-height="1350" data-crop-x="0" data-crop-y="0" data-crop-width="0.979592" data-crop-height="0.792776" data-lazy-loaded="" data-src="global_antimicrobial_resistance/b26dd79e4952997a392d87819ebc2300.png"></div></div>
<div class="sl-block" data-block-type="shape" data-name="shape-299798" data-block-id="ba533da554e75c3256c714cb6f047e1a" style="width: 66px; height: 34px; left: 632px; top: 155px;"><div class="sl-block-content fragment" data-shape-type="arrow-left" data-shape-fill-color="rgb(152, 0, 0)" data-shape-stretch="true" style="z-index: 11;" data-fragment-index="1"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="100%" height="100%" preserveaspectratio="none" viewbox="0 0 66 34"><polygon points="66,10.2 33,10.2 33,0 0,17 33,34 33,23.799999999999997 66,23.799999999999997 66,10.2" class="shape-element" fill="rgb(152, 0, 0)"></polygon></svg></div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 967px; left: 44.5px; top: 22px;" data-name="text-6fab39" data-block-id="77d28caa613e911bd3c3b1f460b839cb"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; color: rgb(152, 0, 0);">
<p><span style="font-size:1.0em"><strong>Huge costs are also incurred post-approval for antibiotics</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-4ce9ab" data-block-id="d69e838678989c9f8f53beeeb466a972" style="height: auto; width: 307px; left: 711px; top: 155px;"><div class="sl-block-content fragment" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 13; line-height: 0.65; color: rgb(152, 0, 0);" data-has-line-height="" data-fragment-index="0">
<p style="text-align:left"><strong><span style="font-size:0.5em">Pediatric dosing and safety studies,</span></strong></p>

<p style="text-align:left"><strong><span style="font-size:0.5em">Pharmacokinetic studies in special populations (i.e. elderly, obese, dialysis)</span></strong></p>

<p style="text-align:left"><strong><span style="font-size:0.5em">Pharmacovigelence (safety)</span></strong></p>

<p style="text-align:left"><strong><span style="font-size:0.5em">Development and validation of susceptibility testing technology/platforms</span></strong></p>

<p style="text-align:left"><strong><span style="font-size:0.5em">Manufacturing and supply chain investments</span></strong></p>

<p style="text-align:left"><strong><span style="font-size:0.5em">5-10 years commitment to monitor resistance through antimicrobial surveillance studies</span></strong></p>

<p style="text-align:left"><strong><span style="font-size:0.5em">...etc</span></strong></p>
</div></div></section><section data-id="e6cf683178d30c664ede84c96b4b3e56"><div class="sl-block" data-block-type="text" style="height: auto; width: 967px; left: 44.5px; top: 22px;" data-name="text-6fab39" data-block-id="68681a60b12cb9a42fdc7078af9413ca"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; color: rgb(152, 0, 0);">
<p><span style="font-size:1.0em"><strong>How can a company overcome these costs?</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-de1068" data-block-id="69761af13111c1088d8b76c075679470" style="height: auto; width: 600px; left: 190px; top: 115.217px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p>Costs &gt;&gt;&gt; Antibiotic price * Units sold</p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-2a5f14" data-block-id="41fdc7b28112bff0ca94946f566b1787" style="width: 860.159px; height: 396.06px; left: 59.9205px; top: 115.217px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="2402" data-natural-height="1106" data-lazy-loaded="" data-src="global_antimicrobial_resistance/17e89e506d291ebb3d28f1f21348bc65.png"></div></div>
<div class="sl-block" data-block-type="text" style="height: auto; width: 1011.5px; left: 0px; top: 479.777px;" data-block-id="e1bc66ba5f5d6a8ecc72044c0469d2a5" data-name="text-c1ead7"><div class="sl-block-content fragment" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 13;" data-fragment-index="0">
<p>Sell lots of antibiotics (high use → drive resistance)</p>

<p>or charge very high prices</p>
</div></div></section><section data-id="41a22f9ae1727608d2dc985b6e653a81"><div class="sl-block" data-block-type="image" data-name="image-48b3e7" data-block-id="04a06be03a902308c12f613fb8bbb08c" style="width: 787.366px; height: 446.24px; left: 104.515px; top: 31.38px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="2382" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/24785204dc6c5ac242df4213d0172a94.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-d5a64d" style="height: auto; width: 600px; left: 227px; top: 530px;" data-block-id="72b15e276e5374067fc39ecec7a1aa0d"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; text-align: center;">
<p><span style="font-size:15px">Source: Financial Times</span></p>
</div></div></section><section data-id="63ecb88329e8b8eb00cf340ae1ff54fb"><div class="sl-block" data-block-type="image" data-name="image-143619" data-block-id="dd5002dc43c40c0255c3ad896d09e3b0" style="width: 684.176px; height: 521.24px; left: 169.912px; top: 15.76px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="1772" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/b3b122c8d4d0fe4cde1bd7e21142d924.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-d5a64d" data-block-id="dfa473922e0b98192dd632ab2ee431ad" style="height: auto; width: 600px; left: 205px; top: 526px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><span style="font-size:0.5em"><span style="color:rgb(51, 51, 51); text-align:start">McKenna, M. </span><em>Nature</em><span style="color:rgb(51, 51, 51); text-align:start"> </span>584<span style="color:rgb(51, 51, 51); text-align:start">, 338–341 (2020).</span></span></p>
</div></div></section><section data-id="cc12bac796d2d3390db009113d54620f"><div class="sl-block" data-block-type="image" data-name="image-91c34b" data-block-id="f52f8d276a3b75e8087136c5446be2c1" style="width: 996.378px; height: 549.473px; left: 27.622px; top: 20.88px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="1088" data-natural-height="600" data-lazy-loaded="" data-src="global_antimicrobial_resistance/0630becb1ccf3226f01d5b2b65ace853.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-d5a64d" style="height: auto; width: 600px; left: 205px; top: 526px;" data-block-id="1d10716e66088a248b01870c7b486078"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><span style="font-size:0.5em"><span style="color:rgb(51, 51, 51); text-align:start">McKenna, M. </span><em>Nature</em><span style="color:rgb(51, 51, 51); text-align:start"> </span>584<span style="color:rgb(51, 51, 51); text-align:start">, 338–341 (2020).</span></span></p>
</div></div></section><section data-id="5db83c3328e5fd503abbf7de4f1472d3"><div class="sl-block" data-block-type="text" data-name="text-5353df" data-block-id="39a28060c3e8b0fb221a61ec6d0cc662" style="height: auto; width: 853px; left: 16px; top: 20.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; text-align: left;">
<p><span style="color:#B22222"><strong>The Archaeogen Story (developer of plazomicin)</strong></span></p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-c13e0a" data-block-id="3a986c5e29cf8f05fbcdd66beeae9b80" style="width: 445.959px; height: 461.337px; left: 272.057px; top: 72px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 11; filter: drop-shadow(rgba(0, 0, 0, 0.5) 0px 0px 5px);"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="1305" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/c675bc44b3e60d1113c8a610bf1de08d.png"></div></div></div>
<div class="sl-block" data-block-type="text" data-name="text-d5a64d" style="height: auto; width: 600px; left: 205px; top: 526px;" data-block-id="6d368206fa468411449931268cdc7417"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p><span style="font-size:15px">NY Times December 25, 2019</span></p>
</div></div></section><section data-id="8075a185a3cc350ed72c61d43924d5cf">

<div class="sl-block" data-block-type="text" data-name="text-179835" data-block-id="84c6342a17d6b906163168572d56901b" style="height: auto; width: 919px; left: 63.5px; top: 62.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; font-size: 75%; line-height: 1.43;" data-has-line-height="">
<ul>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="0" style="text-align:left"><span style="text-align:left">Achaogen a company founded in <strong>2002</strong> developed a new aminoglycoside (plazomicin) that was active against WHO-priority Gram negatives, including carbapenem-resistant Enterbacteriacea (CRE)</span></li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="1" style="text-align:left"><span style="text-align:left">Achaogen raised around <strong>$500+ million in venture capital and public funds</strong> to advance into Phase III trials, not counting non-dilutive support and debt</span></li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="2" style="text-align:left"><span style="text-align:left"><strong>A phase 3 complicated UTI trial was completed in Dec 2016 </strong>demonstrated impressive activity vs. meropenem (EPIC trial)</span></li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="3" style="text-align:left"><span style="font-size:21px">Allergan and Melinta launched ceftazidime-avibactam and meropenem-vaborbactam in 2015 and 2017 respectively- two beta-lactam antibiotics that cover CRE</span></li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="4" style="text-align:left"><span style="text-align:left"><span style="text-align:left">A Phase 3 trial of plazomicin vs. colistin-standard of care in CRE bloodstream infection was started </span>in 2014<span style="text-align:left"> (CARE trial)” but this trial was difficult to enroll with </span><strong>2100 patients screened and 37 randomized over 2.5 years at a cost of 70 million.</strong></span></li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="5" style="text-align:left"><strong><span style="text-align:left">Plazomicin was launched in the U.S. in July 2018</span></strong></li>
	<li class="fragment" data-fragment-index="6" style="text-align:left"><strong><span style="text-align:left">Archaogen filled for Chapter 11 bankruptcy in April 2019</span></strong></li>
</ul>
</div></div>


<div class="sl-block" data-block-type="text" data-name="text-9b2f88" data-block-id="f44e6c1bbbef3a645c330d115082ee1e" style="height: auto; width: 600px; left: 63.5px; top: 10px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; text-align: left;">
<p><strong><span style="color:#B22222">The Archaogen story...</span></strong></p>
</div></div></section><section data-id="c65b2ab7eea6b636ef003781477b4230"><div class="sl-block" data-block-type="text" data-name="text-0c62f5" style="height: auto; width: 1006px; left: 0px; top: 8.33724px;" data-block-id="369622183434071c0aa491c5b5f79e71"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;" dir="ui">
<p><span style="color:#B22222"><strong>The idea of "non-inferiority" is confusing as for infection:</strong></span></p>

<p><span style="color:#B22222"><strong>superiority = something bad <em>but preventable</em> has happened</strong></span></p>
</div></div>

<div class="sl-block" data-block-type="image" data-name="image-a67b94" data-block-id="b0313a0c86bcc8886d71058e7c3d54b7" style="width: 473.408px; height: 429.215px; left: 230.592px; top: 107.785px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 12;"><img style="" data-natural-width="1489" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/426d6a6bc3ddb82b66fc59ecd4f55fee.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-163048" data-block-id="16856e448d8e835ee9c4f40e761852c3" style="height: auto; width: 600px; left: 230.592px; top: 537px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 14;">
<p style="color:rgb(0, 0, 0); text-align:start"><span style="font-size:0.5em">McKinnell, J. A. et al.  <em>New England Journal of Medicine</em>, <em>380</em>(8), 791-793.</span></p>
</div></div></section><section data-id="4a9e09f179896f04364378cfddd86d4c"><div class="sl-block" data-block-type="text" data-name="text-13ee08" data-block-id="9d13c0a132150e670d0bbdb81369f897" style="height: auto; width: 600px; left: 212px; top: 13.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; color: rgb(152, 0, 0);">
<h3><span style="font-size:1.0em"><strong>What has happened since?</strong></span></h3>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-254aa0" data-block-id="609b1958613a391102609d09e652fc1a" style="height: auto; width: 939px; left: 85px; top: 144px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; color: rgb(0, 0, 0); line-height: 1.43;" data-has-line-height="">
<ul>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="0">Ceftazidime-avibactam gained traction in the U.S. market, but 4 years after launch polymyxins still dominate</li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="1">Archaogen assumed meropenem-vabobactam and plazomicin would displace ceftazidime-avibactam and accelerate a decline in polymyxin use.</li>
	<li class="fragment" data-fragment-index="2">Instead, polymyxin use is stable while meropenem-vaborbactam and plazomicin are essentially not used at all<span style="color:#000000">.</span>
</li>
</ul>
</div></div></section><section data-id="d20b65f6cc72e49f1b6215a099d315f4"><div class="sl-block" data-block-type="image" data-name="image-a11f46" data-block-id="91aaaea57d03d2fe68af545be539ec06" style="width: 860.16px; height: 54.13px; left: 87.84px; top: 44.935px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="1017" data-natural-height="64" data-lazy-loaded="" data-src="global_antimicrobial_resistance/632f9afc1dfba2ba63fc8ed86262e139.png"></div></div>
<div class="sl-block" data-block-type="image" data-name="image-ff2c91" data-block-id="2c9a1ce5a49415bfc269de8e6ba1d6f4" style="width: 842.914px; height: 442px; left: 99.575px; top: 99.065px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="left: 0px; top: 0px; width: 848px; height: 507px;" data-natural-width="776" data-natural-height="464" data-crop-x="0" data-crop-y="0" data-crop-width="0.994104" data-crop-height="0.871795" data-lazy-loaded="" data-src="global_antimicrobial_resistance/411c761e2f056ba36f52a2e568a285c9.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-40d7d9" data-block-id="18970611af6e86b2c358400b7555e96b" style="height: auto; width: 776.489px; left: 129.675px; top: 528px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p>Manufacturer of meropenem-vaborbactam</p>
</div></div></section><section data-id="3bd08b670dc815765605fa2a6abecf23"><div class="sl-block" data-block-type="text" data-name="text-8d05cc" data-block-id="6e75e25c6ae64cea3fb47f384ca4c7a5" style="height: auto; width: 600px; left: 237px; top: 249.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<h3><strong><span style="color:#B22222">What can be done to revive the antibiotic pipeline?</span></strong></h3>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-9dde24" data-block-id="ec32df7890401e0874ad8a41184d617f" style="width: 860.33px; height: 573.12px; left: 79px; top: 2.88px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 10; opacity: 0.25;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="1324" data-natural-height="882" data-lazy-loaded="" data-src="global_antimicrobial_resistance/0fe6223120fdfd4ed6f78030ac11af56.png"></div></div></div></section><section data-id="7c480b4a203f98646d939d34a9b22c85"><div class="sl-block" data-block-type="text" data-name="text-942559" data-block-id="a8dadc870ec4628d9f82912af0b726dd" style="height: auto; width: 600px; left: 196px; top: 14.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<h2><span style="color:#B22222">"Push incentives"</span></h2>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-354031" data-block-id="85a0b4897c3da8606f926b209b658968" style="height: auto; width: 957px; left: 42px; top: 208.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; line-height: 1.43;" data-has-line-height="">
<ul>
	<li>Early stage funding</li>
	<li>Occur before regulatory approval by regulatory agency</li>
	<li>Supports many projects, including many that fail before approval</li>
</ul>

<p> </p>
</div></div></section><section data-id="a4cf71a927caa20afad59d5b912bd7de"><div class="sl-block" data-block-type="text" data-name="text-649eb1" data-block-id="0b7edb231bae3301cc3dddb24db8661d" style="height: auto; width: 933.5px; left: 60.25px; top: 103px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10; line-height: 0.91;" data-has-line-height="">
<ul>
	<li>
	<p><span style="font-size:0.7em"><a href="https://www.phe.gov/about/barda/Pages/default.aspx" target="_blank">US Biomedical Advanced Research and Development Authority BARDA</a> (1.2 billion dollars to support Phase 2/3 antibiotic development against 21st century threats including drug-resistant bacteria, supports CARB-X)</span></p>
	</li>
	<li>
	<p><span style="font-size:0.7em"><a href="https://carb-x.org/" target="_blank">CARB-X</a> (550 million, Hits to lead Phase 1 product development of therapeutics, diagnostics and preventatives against WHO and CDC priority drug-resistant bacteria)</span></p>
	</li>
	<li>
	<p><span style="font-size:0.7em"><a href="http://www.gardp.org/" target="_blank">The Global Antibiotic Research and Development Partnership -GARDP</a> (Produce discovery from discovery to delivery including novel therapeutics, optimizing antibiotics, developing combinations. Focused on WHO priority list).</span></p>
	</li>
	<li>
	<p><span style="font-size:0.7em">The <a href="https://www.imi.europa.eu/projects-results/project-factsheets/enable" target="_blank">European Gram Negative AntiBacterial Engine-ENABLE</a></span></p>
	</li>
	<li>
	<p><span style="font-size:0.7em">Novo Holdings <a href="https://www.repair-impact-fund.com/" target="_blank">REPAIR Impact Fund</a> (165 million investment in 165 million investment in lead optimization to Phase I development of therapeutics and diagnostics against WHO priority drug-resistant bacteria</span></p>
	</li>
	<li>
	<p><span style="font-size:0.7em"><a href="http://www.jpiamr.eu/" target="_blank">Joint Programming Initiative on Antimicrobial Resistance -JPIAMR</a>  (novel therapeutics, diagnostics, surveillance, prevention, stewardship, WHO priority pathogens</span></p>
	</li>
</ul>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-e04462" data-block-id="2cfdd8cf995d880251c38dff526e352a" style="height: auto; width: 600px; left: 226px; top: 21px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<h3 style="color:rgb(0, 0, 0)"><span style="font-size:1.0em"><span style="color:rgb(178, 34, 34)">Examples of Push Incentives</span></span></h3>
</div></div></section><section data-id="c37baa659891ec462d71f4761bf7a5cf"><div class="sl-block" data-block-type="text" data-name="text-ac7228" data-block-id="57f781c4ba30396f62c126a0c150afac" style="height: auto; width: 852px; left: 63px; top: 14.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<h3 style="color:rgb(0, 0, 0)"><span style="font-size:1.0em"><span style="color:rgb(178, 34, 34)">Examples of Push Incentives, Cont.</span></span></h3>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-37b1c2" data-block-id="f25f51a7d1a72e3c4ef362af41db6973" style="height: auto; width: 895px; left: 72px; top: 80px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; line-height: 0.91;" data-has-line-height="">
<ul>
	<li style="color:rgb(0, 0, 0)">
	<p><span style="font-size:0.7em"><a href="https://wellcome.org/" target="_blank">Wellcome Trust</a> (175 million drug-resistant infections focused on policy, strengthening evidence for action, clinical trial capabilities and innovative product development including CARB-X</span></p>
	</li>
	<li style="color:rgb(0, 0, 0)">
	<p><span style="font-size:0.7em"><a href="https://www.imi.europa.eu/" target="_blank">Innovative Medicines Initiative</a></span></p>
	</li>
	<li style="color:rgb(0, 0, 0)">
	<p><span style="font-size:0.7em"><a href="https://www.amractionfund.com/" target="_blank">AMR Action Fund</a>. WHO, European Investment Bank, and Wellcome Trust</span></p>
	</li>
	<li style="color:rgb(0, 0, 0)">
	<p><span style="font-size:0.7em"><a href="https://www.gov.uk/government/groups/the-global-amr-innovation-fund" target="_blank">UK AID</a> (315 million pounds funded through the Global AMR innovation fund and the Fleming Fund to help LMICs tackle AMR).</span></p>
	</li>
	<li style="color:rgb(0, 0, 0)">
	<p><span style="font-size:0.7em">The <a href="https://www.gesundheitsforschung-bmbf.de/en/GlobalAMRHub.php" target="_blank">German Federal Ministry of Education and Research</a> support of national research programs as well as contributions to international initiatives like CARB-X, GARDP, and JPIAMR.</span></p>
	</li>
	<li style="color:rgb(0, 0, 0)">
	<p><span style="font-size:0.7em"><a href="https://www.gatesfoundation.org/" target="_blank">Bill &amp; Melinda Gates Foundation</a>(124 million targeting drug-resistant infections in low-middle income countries (LMICs), disease surveillance, vaccine development, economic modeling, and CARB-X</span></p>
	</li>
	<li style="color:rgb(0, 0, 0)">
	<p><span style="font-size:0.7em"><a href="https://www.niaid.nih.gov/research/antimicrobial-resistance" target="_blank">U.S. National Institutes of Health</a> (1.4 billion dollars funding basic research, academic industry startup partnerships, and other research and development against bacterial threats, for vaccines, therapeutics and diagnostics</span></p>
	</li>
</ul>
</div></div></section><section data-id="c4a822d676ca9ab2535246ffd38f5130"><div class="sl-block" data-block-type="text" data-name="text-13100b" data-block-id="45368ba851089baf1cb9dcb255f403d2" style="height: auto; width: 600px; left: 212px; top: 21px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<h3><span style="color:#B22222"><strong>Pull incentives</strong></span></h3>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-7843cf" data-block-id="f3ed4a2b754104e2ef290c7c5848df8f" style="width: 617.434px; height: 510.12px; left: 35.413px; top: 65.88px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="1634" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/b26dd79e4952997a392d87819ebc2300.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-d53693" data-block-id="aef6ede7444bd2e25e84b5fb1ea89664" style="height: auto; width: 348px; left: 638px; top: 191px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p style="text-align: left;">Pull incentives are paid only after regulatory approval and hence only successful products are supported</p>

<p> </p>
</div></div></section><section data-id="56c98fe3e8d128b2510b03c29b6f063d"><div class="sl-block" data-block-type="text" data-name="text-5a0709" data-block-id="dff618666633be3998e84e4f65df16c7" style="height: auto; width: 952px; left: 42px; top: 21px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<h3><span style="color:#B22222"><strong>Antibiotic benefits go beyond simple use</strong></span></h3>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-69b427" data-block-id="e20e88359ebc0a1cd53574103c14fbe5" style="height: auto; width: 940px; left: 42px; top: 137px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; line-height: 1.43;" data-has-line-height="">
<ul>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="0">
<span style="color:#B22222">Enabling value</span>: <span style="font-size:24pt">Many surgical and medical procedures rely on prophylaxis with effective antibiotics. </span>
</li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="1">
<span style="color:#B22222">Option or insurance value</span>: <span style="font-size:24pt">We may want to have an antibiotic in reserve before we really need it, so it’s ready if resistance arises or worsens. </span>
</li>
	<li class="fragment" data-fragment-index="2"><span style="font-size:24pt"><span style="color:#B22222">Diversity value</span>: Having multiple antibiotics may reduce selection pressure and delay resistance</span></li>
</ul>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-ace3ea" data-block-id="1159d7bfe0553e3caa640d3834f39cb4" style="height: auto; width: 600px; left: 95px; top: 524.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p><span style="font-size:0.5em">Slide: John Rex, M.D.</span></p>
</div></div></section><section data-id="1380b8a739ea8c6800cd82c7e80e1ff2"><div class="sl-block" data-block-type="image" data-name="image-78a755" style="width: 316.047px; height: 326.777px; left: 42.5046px; top: 105.223px; min-width: 1px; min-height: 1px;" data-block-id="07c277403757fd251647c536361afd53"><div class="sl-block-content" style="z-index: 10; border-style: solid; border-width: 1px;"><img style="" data-natural-width="324" data-natural-height="335" data-lazy-loaded="" data-src="global_antimicrobial_resistance/358cd1990793bc69dcb95eb70aa76422.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-ace3ea" style="height: auto; width: 600px; left: 200.528px; top: 537px;" data-block-id="dc9401f2f9cfcdf5542657a239e67847"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><span style="font-size:0.5em">Slide: John Rex, M.D.</span></p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-9b6bbd" data-block-id="777a72ea11f97730e33f76109bd7371f" style="height: auto; width: 966px; left: 0px; top: 21px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<h3><span style="font-size:1.0em"><span style="color:#B22222"><strong>Antibiotics are the "fire extinguishers" of medicine</strong></span></span></h3>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-0a05a7" data-block-id="347cd59e51c22a46f387dbc49cc3ecee" style="height: auto; width: 649px; left: 358.552px; top: 119px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 13;">
<ul>
	<li>Nobody wishes to put out a fire</li>
	<li>Firefighters perform regular maintenance and training to ensure they are ready 24/7 as a precaution to fight fires</li>
	<li>
	<p>We pay firefighters to be available and prepared so they can come to our rescue when we need them</p>
	</li>
</ul>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-ff919a" data-block-id="d2a562c21446132f970579ac6bcb3fad" style="height: auto; width: 1008.5px; left: 7.75px; top: 441.5px;"><div class="sl-block-content fragment" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 14; line-height: 0.91;" data-has-line-height="" data-fragment-index="0">
<p><span style="font-size:0.7em">A fire fighter uses a hose to subdue flames engulfing a home while a physician uses antibiotics to stop an infection in your body. We need to be prepared for fires – the flame kind and the medical kind</span></p>
</div></div></section><section data-id="e63cbae2b2a9c1287389e81eb33bb615"><div class="sl-block" data-block-type="text" data-name="text-8f85df" data-block-id="f571b35dc8987783260de1b1b7f18624" style="height: auto; width: 675.232px; left: 166.768px; top: 21px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<h3><strong><span style="color:#B22222">Pull incentives: the NETFLIX Model</span></strong></h3>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-a85ed1" data-block-id="6e0a3f7778b4fc9e7b7b588892fca59f" style="width: 337.186px; height: 337.186px; left: 343.407px; top: 61.1571px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="119" data-natural-height="119" data-lazy-loaded="" data-src="global_antimicrobial_resistance/723f95d4eb80215e6a93e117eafa4513.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-bb2e4c" data-block-id="2b06cca41766832ee6ce49d2eff405c4" style="height: auto; width: 832.464px; left: 136.768px; top: 387px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p style="text-align:left"><span style="color:rgb(32, 33, 36); text-align:left">Netflix is a <strong>subscription-based</strong> streaming service that allows </span>our members to watch TV shows and movies without commercials on an internet-connected device<span style="color:rgb(32, 33, 36); text-align:left">.</span></p>

<p style="text-align:left"><span style="color:rgb(32, 33, 36); text-align:left">You pay a monthly fee whether or not you watch movies.</span></p>
</div></div></section><section data-id="0b4596f0a4583f7ed87ab6493411daef"><div class="sl-block" data-block-type="text" data-name="text-21b292" data-block-id="25224d11aed0fc9c74470daaaf66cd2f" style="height: auto; width: 600px; left: 204.425px; top: 7.65654px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<p><span style="font-size:1.2em"><span style="color:#B22222"><strong>How would a Netflix-like pull incentive work for antibiotics?</strong></span></span></p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-d662e0" data-block-id="50b94cad8fb659fa143bb96afa4041c7" style="height: auto; width: 969px; left: 27.5px; top: 124.944px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<ul>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="0"><span style="font-size:0.9em"><strong><span style="color:#B22222">UK Example</span>:</strong>  Two antibiotics from a pool of candidates are selected- must be an antimicrobial approved in the last 1.5−3 years, and the other will be a late-stage pipeline product expected to be approved by the end of 2020</span></li>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="1"><span style="font-size:0.9em">Any company to be considered for the model must have a demonstrated commitment to relevant environmental and access standards as described in the <a href="https://accesstomedicinefoundation.org/%20publications/2020-antimicrobial-resistance-benchmark." target="_blank">AMR Benchmark</a></span></li>
	<li class="fragment" data-fragment-index="2">
<span style="font-size:0.9em">National Institute for Health and Care Excellence (NICE) performs a cost-effectiveness analysis, then computes a fair "</span><span style="font-size:27px">subscription</span><span style="font-size:0.9em"> price"</span>
</li>
</ul>
</div></div></section><section data-id="3f47f770093b05f2d7666f183d5d949b"><div class="sl-block" data-block-type="text" data-name="text-61f096" data-block-id="b432f9b5df2628d776123c1d2757315e" style="height: auto; width: 926.144px; left: 48.928px; top: 144px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<ul>
	<li class="fade-in-then-semi-out fragment" data-fragment-index="0" style="color:rgb(0, 0, 0)"><span style="font-size:0.9em">National Health Service (NHS) England then enters into commercial negotiations with the proprietors of the<strong> </strong>two selected products to agree on payments, which will take the form of an annual fixed fee of up to £10 million per product</span></li>
	<li class="fragment" data-fragment-index="1" style="color:rgb(0, 0, 0)"><span style="font-size:0.9em">This maximum annual fee is based on a calculation what approximately England’s “fair share” would be of the proposed US <span style="color:#B22222">$2−4 billion financial incentive needed</span>, per new antimicrobial, globally, to revitalise the antimicrobial pipeline</span></li>
</ul>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-21b292" style="height: auto; width: 600px; left: 202.112px; top: 16.9089px;" data-block-id="b8a7dfa64c7fb79edd4f71157995c9a9"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><span style="font-size:1.2em"><span style="color:#B22222"><strong>How would a Netflix-like pull incentive work for antibiotics?</strong></span></span></p>
</div></div></section><section data-id="da67ff6141d91676e52751423291f209"><div class="sl-block" data-block-type="text" data-name="text-ee2f20" data-block-id="2bb790ae78f699a583bf58079505d049" style="height: auto; width: 600px; left: 174px; top: 24.4702px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<p><strong><span style="color:#B22222">More detail on antibiotic pull incentives being considered by different countries...</span></strong></p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-6c3fbe" style="width: 860.159px; height: 419.59px; left: 61.1028px; top: 114.058px; min-width: 1px; min-height: 1px;" data-block-id="26dc767375944bd3cfb57ee3489bc977"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="861" data-natural-height="420" data-lazy-loaded="" data-src="global_antimicrobial_resistance/6df52e2f92bb5aba565bfd99a51d5b28.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-4eb167" data-block-id="0992e883e8802158f9c60049f57e4b33" style="height: auto; width: 600px; left: 158px; top: 533.648px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p><span style="font-size:0.5em"><span style="color:rgb(51, 51, 51); text-align:start">Gotham, D. </span><em>et al.</em><span style="color:rgb(51, 51, 51); text-align:start"> </span><span style="color:rgb(51, 51, 51); text-align:start"> </span><em>Health Policy </em>125</span><span style="color:rgb(51, 51, 51); text-align:start"><span style="font-size:0.5em">, 296–306 (2021)</span></span></p>
</div></div></section><section data-id="d51fce51ce8a38722046e89598c5291c"><div class="sl-block" data-block-type="text" data-name="text-ee2f20" style="height: auto; width: 824px; left: 62px; top: 21.4702px;" data-block-id="efa28984f215073eb8b982c4f795053b"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<p><strong><span style="color:#B22222">More on pull incentives...see online handout!</span></strong></p>
</div></div>
<div class="sl-block" data-block-type="iframe" data-name="iframe-eaf709" data-block-id="3b5f93a58177d3e7fd8258119fa7df88" style="width: 747.49px; height: 461.993px; left: 121.51px; top: 87.035px;"><div class="sl-block-content" style="z-index: 11;"><iframe allowfullscreen="" allow="fullscreen" data-src="https://www.ft.com/video/adada10f-5747-4976-a3e0-958b0165e0ef" sandbox="allow-forms allow-scripts allow-popups allow-same-origin allow-pointer-lock allow-presentation"></iframe></div></div></section><section data-id="8b7dfe6465315398faabeb7bd2d4638b"><div class="sl-block" data-block-type="text" style="width: 861px; left: 87px; top: 155px; height: auto;" data-block-id="b105eaf2c0fea0ff78dd48a7e374fe6d"><div class="sl-block-content" data-placeholder-tag="h1" data-placeholder-text="Title Text" style="z-index: 11; color: rgb(152, 0, 0);">
<h3> </h3>

<p>Lack of antibiotic availability due to supply chain problems</p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-4c854f" data-block-id="23537220f2a504f70fb4288927cdf271" style="width: 992.529px; height: 576px; left: 16.706px; top: 0px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 10; opacity: 0.2; transform: rotate(0deg);"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="1668" data-natural-height="968" data-lazy-loaded="" data-src="global_antimicrobial_resistance/abb0bb8acfe98ad035278fc9e89e0414.png"></div></div></div></section><section data-id="27a80c29a34bdde06d9f8fbf2019cfab"><div class="sl-block" data-block-type="text" data-name="text-cd5c2e" data-block-id="ba922456f2e601c2a1125b5019c8994d" style="height: auto; width: 955px; left: 45px; top: 12.5px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 10;">
<p><font color="#b22222" style="font-size: 1em;"><strong>Increasing frequency of shortages for injectable generic antibiotics-a </strong></font><font color="#b22222"><strong>contributor</strong></font><font color="#b22222" style="font-size: 1em;"><strong> to AMR</strong></font></p>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-92f091" data-block-id="30bcf8311e180fd18510f3fe5989872e" style="width: 768.169px; height: 450.099px; left: 127.916px; top: 98.4392px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="1280" data-natural-height="750" data-lazy-loaded="" data-src="global_antimicrobial_resistance/9f58e045887ea078b6708bc9af264560.jpg"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-e09ac9" data-block-id="0d443435ea429d2011824885e32c5923" style="height: auto; width: 600px; left: 200.409px; top: 536px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p><span style="font-size:0.5em"><span style="text-align:start">Shafiq, N. </span><em>et al.</em><span style="text-align:start"> </span><em>BMJ Global Health</em><span style="text-align:start"> </span>6<span style="text-align:start">, e006961 (2021).</span></span></p>
</div></div></section><section data-id="564e7c6d8febd38f1b3648e643773669"><div class="sl-block" data-block-type="image" data-name="image-c32c4e" data-block-id="c7c2f6813fd2a42286ce89f02e040d0a" style="width: 1047.47px; height: 576px; left: 0px; top: 3.55271e-15px; min-width: 1px; min-height: 1px;"><div class="sl-block-style" style="z-index: 10; opacity: 0.2;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="2455" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/dfecc1da534b800edfd6390a8ffd75a9.png"></div></div></div>
<div class="sl-block" data-block-type="text" data-name="text-32669b" data-block-id="7d05e1d64e31f4655de1d74523b278a2" style="height: auto; width: 600px; left: 401.201px; top: 259px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<h3><span style="color:#B22222"><span style="font-size:1.0em"><strong>Antibiotic access in low-middle income countries</strong></span></span></h3>
</div></div>
<div class="sl-block" data-block-type="image" data-name="image-0a7289" style="width: 328.363px; height: 426.24px; left: 66.637px; top: 72px; min-width: 1px; min-height: 1px;" data-block-id="5ae2935319c5f57c4703bc717877b0ce"><div class="sl-block-content" style="z-index: 12;"><img style="" data-natural-width="1040" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/11bd4b23fab0878229393cdc40a93e5b.png"></div></div></section><section data-id="942d6e26549b23dae68cfbcce9569412"><div class="sl-block" data-block-type="text" style="width: 861px; left: 100.661px; top: 46.5px; height: auto;" data-block-id="5a43eeafc369fa692d18006aa6091b60"><div class="sl-block-content" data-placeholder-tag="h2" data-placeholder-text="Title Text" style="z-index: 10;">
<h3><span style="color:#B22222">The challenges in many LMICs</span></h3>
</div></div>
<div class="sl-block" data-block-type="text" style="width: 861px; left: 87px; top: 198.119px; height: auto;" data-block-id="7b5e15816c5f48c7d4a3a27a460d24d4"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<ul>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="0">Limited access to basic sanitation or health care increases the risk and spread of antimicrobial resistance</li>
	<li class="fragment" data-fragment-index="1">Antibiotics, often available without prescription, are often used for substitutes of clean food, water and access to vaccines or diagnostics</li>
	<li class="fragment" data-fragment-index="2">Antibiotic access and resistance cannot be addressed effective without addressing contributing factors</li>
</ul>
</div></div></section><section data-id="619bc03de979923a3b26c2617663d0e3"><div class="sl-block" data-block-type="image" data-name="image-465d1b" data-block-id="9da87aef383e858bc68188ea3a3e7d2f" style="width: 633.533px; height: 426.24px; left: 195.233px; top: 94.725px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="1522" data-natural-height="1024" data-lazy-loaded="" data-src="global_antimicrobial_resistance/a0158adcedc19b03937e1590b0982522.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-778b5c" data-block-id="cd9c6386800cdf8e8766db7b45cbfe6c" style="height: auto; width: 887.978px; left: 79px; top: 520.965px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><span style="font-size:0.5em"><span style="color:rgb(51, 51, 51); text-align:start">Frost et al.  Access </span><span style="color:rgb(51, 51, 51); text-align:start">Barriers</span><span style="color:rgb(51, 51, 51); text-align:start"> to </span><span style="color:rgb(51, 51, 51); text-align:start">Antibiotics</span><span style="color:rgb(51, 51, 51); text-align:start">. </span><span style="color:rgb(51, 51, 51); text-align:start">Center for Disease Dynamics, Economics &amp; Policy (CDDEP)</span></span><span style="color:rgb(51, 51, 51); text-align:start"><span style="font-size:0.5em">, 2019.</span></span></p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-7c18ab" data-block-id="ca06d512a078e5f237b67bdde00c4037" style="height: auto; width: 1014.4px; left: 27.7569px; top: 0px;"><div class="sl-block-style" style="z-index: 12; transform: rotate(0deg);"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p><strong><span style="color:#B22222">Global antibiotic consumption (2000 to 2015). Change in antibiotic consumption rate per 1,000 inhabitants per day.</span></strong></p>

<p> </p>
</div></div></div></section><section data-id="8bc0c88b29967c4d82adeefcf37c1431"><div class="sl-block" data-block-type="image" data-name="image-04a5e0" data-block-id="dcb859a2d7946791ecb3c23aee5db405" style="width: 414.293px; height: 576px; left: 59.707px; top: 0px; min-width: 1px; min-height: 1px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="971" data-natural-height="1350" data-lazy-loaded="" data-src="global_antimicrobial_resistance/63755db8eed6d74c368bc0c53bb8e655.png"></div></div>
<div class="sl-block" data-block-type="text" data-name="text-a3b584" data-block-id="271a6376cb3b67eeadc26a088a5887be" style="height: auto; width: 600px; left: 332px; top: 0px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><strong><span style="color:#B22222">Antibiotic consumption rate in defined daily doses (DDDs) per 1,000 inhabitants per day by country in 2015</span></strong></p>

<p> </p>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-df5bfa" data-block-id="5d27f3cf064cb3aee1481dc15c4d05ab" style="height: auto; width: 431.145px; left: 500.855px; top: 242.5px;"><div class="sl-block-style" style="z-index: 12; filter: drop-shadow(rgb(255, 255, 255) 0px 0px 5px);"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12; border-width: 1px;">
<p style="text-align: left;"><span style="font-size:0.7em"><span style="color:rgb(51, 51, 51); text-align:start">DDD is a statistical measure of drug consumption, defined by the World Health Organization, and is used to standardize the comparison of drug usage between different drugs or between different health care environments</span></span></p>
</div></div></div>
<div class="sl-block" data-block-type="text" data-name="text-778b5c" style="height: auto; width: 320.117px; left: 703.883px; top: 537px;" data-block-id="cecd6ee117f8292089e6d9c1104a5a17"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 13;">
<p><span style="font-size:0.5em"><span style="color:rgb(51, 51, 51); text-align:start">Frost et al. </span><span style="color:rgb(51, 51, 51); text-align:start">CDDEP</span></span><span style="color:rgb(51, 51, 51); text-align:start"><span style="font-size:0.5em">, 2019.</span></span></p>
</div></div></section><section data-id="e959d53a20bda57fad96ee42d3699388"><div class="sl-block" data-block-type="text" style="width: 1039.65px; left: -0.003px; top: 16.5px; height: auto;" data-block-id="854326ff2c4c45f929ef8231ba069603"><div class="sl-block-content" data-placeholder-tag="h2" data-placeholder-text="Title Text" style="z-index: 10;">
<h3><span style="color:#B22222">Barrier 1: Irrational selection and use of antibiotics</span></h3>
</div></div>
<div class="sl-block" data-block-type="text" style="width: 861px; left: 81.5px; top: 159.432px; height: auto;" data-block-id="287340fdccd951adf4341b4d5f57bab1"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<ul>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="0">Incentives for sale and inappropriate use of antibiotics- i.e. conflict of interest common such as payments linked to antibiotic prescribed</li>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="1">Over the counter antibiotic sales</li>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="2">Frequent prescribing by non-professionals</li>
	<li class="fragment" data-fragment-index="3">Multiple different regulatory agencies- difficult cost justification for registration in many LMICs</li>
</ul>
</div></div>
<div class="sl-block" data-block-type="text" data-name="text-778b5c" style="height: auto; width: 320.117px; left: 343.043px; top: 536px;" data-block-id="6154c9027ec1a0af9e9ce503d34214de"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 12;">
<p><span style="font-size:0.5em"><span style="color:rgb(51, 51, 51); text-align:start">Frost et al. </span><span style="color:rgb(51, 51, 51); text-align:start">CDDEP</span></span><span style="color:rgb(51, 51, 51); text-align:start"><span style="font-size:0.5em">, 2019.</span></span></p>
</div></div></section><section data-id="c1ecf0e889a200cb0b7e861dbedc50d3"><div class="sl-block" data-block-type="table" data-name="table-a72dd4" data-block-id="aed515620aace10f938820124571e2f1" style="height: auto; min-width: 120px; width: 800px; left: 105.096px; top: 15.5px;"><div class="sl-block-content" style="z-index: 10; font-size: 50%;" data-table-rows="5" data-table-cols="4"><table><tbody>
<tr>
<th style="width: 61px;"></th>
<th>CDDEP Recommendation</th>
<th>Stakeholders</th>
<th>Rationale</th>
</tr>
<tr>
<td style="width: 61px;">1</td>
<td>Encourage R&amp;D of new or improved antibiotics, diagnostic tests, vaccines, alternatives to antibiotics for bacterial infections</td>
<td>Countries, regional collaboratos, WHO and other international bodies, pharmaceutical industry, academia</td>
<td>At a global scale, higher investment in novel antibiotics, temperature-stable formulations, and rapid diagnostic tests</td>
</tr>
<tr>
<td style="width: 61px;">2</td>
<td>Support the registration of antibiotics in more countries according to clinical need</td>
<td>WHO and other international bodies, national governments, policymakers, regulators, pharmaceutical industry</td>
<td>Efforts at the national, regional, and global levels to support drug registration could reduce the upfront cost of accessing less attractive markets and benefit patients by making life-saving drugs available.<br>
Newer drugs coming to market are likely to be introduced by small and medium-size enterprises that may not have the expertise or resources to register in multiple countries. However, this cost should not be a barrier.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Regulators and policymakers</td>
<td>In many instances, regulations and requirements could be aligned across countries and simplified to reduce costs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmaceutical companies</td>
<td>Plans for registration should be part of the development process.</td>
</tr>
</tbody></table></div></div></section><section data-id="68cfda498200818e3d11519c9b6c9080"><div class="sl-block" data-block-type="table" data-name="table-a72dd4" style="height: auto; min-width: 120px; width: 800px; left: 101.626px; top: 15.5px;" data-block-id="757701659cee12193bf8d47976a2ea97"><div class="sl-block-content" style="z-index: 10; font-size: 50%;" data-table-rows="3" data-table-cols="4"><table><tbody>
<tr>
<th style="width: 61px;"></th>
<th>CDDEP Recommendation</th>
<th><strong>Stakeholders</strong></th>
<th><strong>Rationale</strong></th>
</tr>
<tr>
<td style="width: 61px;">3</td>
<td>Establish standards of practice and national treatment guidelines.</td>
<td>WHO, countries, experts and their professional associations, hospitals and community care facilities</td>
<td>The WHO should issue a call to<br>
action for all professional associations and councils involved in prescribing practices to develop clinical guidelines for treating infectious diseases at all levels of healthcare.</td>
</tr>
<tr>
<td style="width: 61px;">4</td>
<td>Generate awareness and educate patients and prescribers.</td>
<td>Non governmental organizations (NGOs), advocacy groups, professional bodies,WHO offices at all levels, health ministries, and local institutions (hospitals, clinics, schools, churches, etc.)</td>
<td>Information about the price and quality of antibiotics approved for use in a country will support rational prescribing and use, as will surveillance data on local antibiotic resistance profiles.<br>
NGOs, professional bodies, and<br>
advocacy groups can use existing communications channels to educate patients and prescribers about drug quality and rational antibiotic use. Such information will empower consumers who purchase drugs out-of-pocket to demand quality antibiotics while increasing<br>
price competition among suppliers and removing poor-quality suppliers from the market.</td>
</tr>
</tbody></table></div></div></section><section data-id="556557613e0f20b0b4848ce1b6685afb"><div class="sl-block" data-block-type="image" data-name="image-90a139" data-block-id="977f75aad4e59ac635a2e772d9994de6" style="width: 633.24px; height: 315.24px; left: 374px; top: 249.88px;"><div class="sl-block-content" style="z-index: 10;"><img style="" data-natural-width="2294" data-natural-height="1142" data-src="global_antimicrobial_resistance/6cdcd5b77fdd715f721b2eb3da336637.png"></div></div>
<div class="sl-block" data-block-type="image" data-name="image-ba7e28" data-block-id="76a4f9d8ffa8d26cc79d1ef560ece1cb" style="width: 290.79px; height: 426.239px; left: 61.21px; top: 72px;"><div class="sl-block-content" style="z-index: 11;"><img style="" data-natural-width="921" data-natural-height="1350" data-src="global_antimicrobial_resistance/0e5b4db4e348119b7b56875b26e08f14.png"></div></div>
<div class="sl-block" data-block-type="text" style="width: 1039.65px; left: 0px; top: 6.93924px; height: auto;" data-block-id="374770c0fcfe9fd16f920da84d060bbe" data-name="text-3a576d"><div class="sl-block-content" data-placeholder-tag="h2" data-placeholder-text="Title Text" style="z-index: 12;">
<h3><span style="color:#B22222">Progress in regulation and rationale use</span></h3>
</div></div></section><section data-id="4ba5076db35f4dc863c155e2dcb9f402"><div class="sl-block" data-block-type="table" data-name="table-a72dd4" style="height: auto; min-width: 120px; width: 800px; left: 112px; top: 108px;" data-block-id="14ab771ebef7fb3cd445c4029f4d2521"><div class="sl-block-content" style="z-index: 10; font-size: 50%;" data-table-rows="2" data-table-cols="4"><table><tbody>
<tr>
<th style="width: 61px;"></th>
<th>CDDEP Recommendation</th>
<th><strong>Stakeholders</strong></th>
<th><strong>Rationale</strong></th>
</tr>
<tr>
<td style="width: 61px;">5</td>
<td>Reduce conflict of interest and incentives that lead to inappropriate antibiotic use.</td>
<td>Regulators, NGOs, doctors, and patients</td>
<td>Conflicts of interest between prescribers and the vendors of pharmaceuticals can be addressed by regulating gifts from drug companies and promoting the enforced or voluntary declaration of such gifts</td>
</tr>
</tbody></table></div></div>
<div class="sl-block" data-block-type="text" data-name="text-778b5c" style="height: auto; width: 320.117px; left: 703.883px; top: 537px;" data-block-id="783e626f2f21dc95e5e0f17c14aa278e"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><span style="font-size:0.5em"><span style="color:rgb(51, 51, 51); text-align:start">Frost et al. </span><span style="color:rgb(51, 51, 51); text-align:start">CDDEP</span></span><span style="color:rgb(51, 51, 51); text-align:start"><span style="font-size:0.5em">, 2019.</span></span></p>
</div></div></section><section data-id="b0101685f4944d9e2138d9130733033a"><div class="sl-block" data-block-type="text" style="width: 861px; left: 79px; top: 12.5891px; height: auto;" data-block-id="b12fc81a0d38a80400376e8d95d69905"><div class="sl-block-content" data-placeholder-tag="h2" data-placeholder-text="Title Text" style="z-index: 10;">
<h2><strong><span style="color:#B22222">Summary</span></strong></h2>
</div></div>
<div class="sl-block" data-block-type="text" style="width: 861px; left: 61.3389px; top: 135.007px; height: auto;" data-block-id="813036f51e4fde9ae7232d92da5b57dd"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<ul>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="0">Both scientific and economic challenges for developing new antibiotics has caused many companies abandon development of new antibiotics</li>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="1">The depleted antibiotic pipeline and increasing resistance has major public health implications for medicine in both high-income and low-income countries</li>
	<li class="fragment fade-in-then-semi-out" data-fragment-index="2">While antibiotic overuse is the major concern in high-income countries, access to effective and affordable antibiotics in many LMICs is inadequate but increasing with less infrastructure to support rationale use </li>
</ul>
</div></div></section><section data-id="6b8036e13336731418b9f48f841acb30"><div class="sl-block" data-block-type="text" style="width: 966.245px; left: 43.5px; top: 34.5634px; height: auto;" data-block-id="de84c5ab5eb5a1ac93e9c4d35a4d65cb"><div class="sl-block-style" style="z-index: 10; transform: rotate(0deg);"><div class="sl-block-content" data-placeholder-tag="h2" data-placeholder-text="Title Text" style="z-index: 10;">
<h3><span style="color:#B22222">Barrier 2: Antibiotics are not affordable for many in LMICs and government funding for health is low</span></h3>
</div></div></div>
<div class="sl-block" data-block-type="text" style="width: 861px; left: 81.5px; top: 202.642px; height: auto;" data-block-id="5263b4048469bd3bd61c9a8185af6aa9"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<ul>
	<li>Less than 10% of public spending in many LMICs goes to healthcare</li>
	<li>Less than half of essential medicines are available in many countries</li>
</ul>
</div></div></section><section data-id="56743e16bef78e9ca0e918f8de709c6b"><div class="sl-block" data-block-type="table" data-name="table-a72dd4" style="height: auto; min-width: 120px; width: 800px; left: 105.061px; top: 36.2946px;" data-block-id="08a90118248d63da1adf76ccb93cf75a"><div class="sl-block-content" style="z-index: 10; font-size: 60%;" data-table-rows="2" data-table-cols="4"><table><tbody>
<tr>
<th style="width: 61px;"></th>
<th>CDDEP Recommendation</th>
<th><strong>Stakeholders</strong></th>
<th><strong>Rationale</strong></th>
</tr>
<tr>
<td style="width: 61px;">6</td>
<td>Explore innovative funding of essential antibiotics</td>
<td>UNICEF, WHO, national governments, pharmaceutical manuscfactures</td>
<td>Countries with less purchasing<br>
power could pool their resources for procurement under arrangements similar to Gavi (the vaccine alliance)<br>
or the Global Fund. UNICEF/WHO might coordinate procurement and distribution. Besides helping LMICs increase their purchasing power,<br>
such an arrangement would support quality manufacturers while driving out substandard suppliers.</td>
</tr>
</tbody></table></div></div>
<div class="sl-block" data-block-type="text" data-name="text-f5a643" data-block-id="33a793da52387081be4de51c5ead904a" style="height: auto; width: 600px; left: 190px; top: 504px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11;">
<p><em>We will focus on this topic more in Module 3</em></p>
</div></div></section><section data-id="b53e58406e2c3cd56ab1da22e63a2922"><div class="sl-block" data-block-type="text" style="width: 1009.75px; left: 0px; top: 31.0938px; height: auto;" data-block-id="03f69b78d8bc32e9fab33378505b190d" data-name="text-cfbd30"><div class="sl-block-style" style="z-index: 10; transform: rotate(0deg);"><div class="sl-block-content" data-placeholder-tag="h2" data-placeholder-text="Title Text" style="z-index: 10;">
<h3><span style="font-size:0.9em"><span style="color:#B22222">Barrier 3: Weak health systems, unreliable supply chains and poor quality control fail to deliver antibiotics to patients in need</span></span></h3>
</div></div></div>
<div class="sl-block" data-block-type="text" data-name="text-086da6" data-block-id="f5868a928db0de962a70f2e084e1a23c" style="height: auto; width: 892.604px; left: 95px; top: 260.404px;"><div class="sl-block-content" data-placeholder-tag="p" data-placeholder-text="Text" style="z-index: 11; text-align: left;">
<ul>
	<li>Out-of-pocket payments for antibiotics either limit access or push people further into poverty</li>
	<li>In remote areas, transportation costs and accompanying relatives may be unaffordable</li>
	<li>Antibiotics are often not available or may be of poor quality</li>
</ul>
</div></div></section><section data-id="d48b473fd6b982f78986fb16226968be"><div class="sl-block" data-block-type="table" data-name="table-a72dd4" style="height: auto; min-width: 120px; width: 800px; left: 99.469px; top: -58.5185px;" data-block-id="125cfc9fc7698b1871b0cc5cff09709c"><div class="sl-block-content" style="z-index: 10; font-size: 50%;" data-table-rows="2" data-table-cols="4"><table><tbody>
<tr>
<th style="width: 61px;"></th>
<th>CDDEP Recommendation</th>
<th><strong>Stakeholders</strong></th>
<th><strong>Rationale</strong></th>
</tr>
<tr>
<td style="width: 61px;">7</td>
<td>Ensure the quality of antibiotics, and strengthen pharmaceutical regulatory capacity</td>
<td>WHO, national and regional regulators, countries, pharmaceutical suppliers and manufacturers</td>
<td>WHO support and coordination, national and regional regulators could collaborate to support quality assurance and avoid duplication of effort across countries;<br>
Rapid information exchange for pharmacovigilance, information on poor- quality suppliers, and sharing of best practices and innovation will help drive substandard and falsified antibiotics from the market.<br>
An international entity, such as the WHO, could provide surveillance, monitoring, and compliance testing for antibiotic quality. Such work would support LMICs' regulatory authorities and also ensure the integrity of the supply chain from the dominant suppliers in India and China. It could also establish standards for generic antibiotics and fixed-dose combinations, which are commonly used in LMICs, and support the industry in self- regulation.</td>
</tr>
</tbody></table></div></div></section><section data-id="f8abe2a67db66f5ba95965fe57e9385b"><div class="sl-block" data-block-type="table" data-name="table-a72dd4" style="height: auto; min-width: 120px; width: 800px; left: 91.2167px; top: 91.8316px;" data-block-id="b78ea5a9b75f91ff859c5c3ada0a2615"><div class="sl-block-content" style="z-index: 10; font-size: 50%;" data-table-rows="2" data-table-cols="4"><table><tbody>
<tr>
<th style="width: 61px;"></th>
<th>CDDEP Recommendation</th>
<th><strong>Stakeholders</strong></th>
<th><strong>Rationale</strong></th>
</tr>
<tr>
<td style="width: 61px;">8</td>
<td>Encourage local manufacturing for cost-effective antibiotics.</td>
<td>Countries, regional collaborations, pharmaceutical industry, including drug R&amp;D and manufacturers</td>
<td>Development and diversification of local manufacturers can help ensure the steady supply of essential, quality-assured antibiotics so that countries can meet their own needs. This should be supported through regional collaborations of countries such as the African Union.</td>
</tr>
</tbody></table></div></div></section>
			</div>
		</div>

		<script>
			var SLConfig = {"deck": {"id":2306725,"slug":"global_antimicrobial_resistance","title":"Module 2: Crises in New Antibiotic Development","description":"Module 1. 97039-Global Heath, Antimicrobial Drugs and Vaccines","width":1024,"height":576,"margin":0.05,"visibility":"all","published_at":"2021-12-21T13:44:51.178Z","sanitize_messages":null,"thumbnail_url":"https://s3.amazonaws.com/media-p.slid.es/thumbnails/9716afc721b8ea58424a6e71f5ee444a/thumb.jpg?1640616282","view_count":1,"user":{"id":1649663,"username":"russelllewis","name":"Russell Lewis","description":"","thumbnail_url":"https://lh3.googleusercontent.com/a-/AOh14GjNeo394H6wsuhogeCWfHa2KbRTq-YOtqybU6xsZQ=s96-c","account_type":"pro","team_id":null,"settings":{"id":9491572,"present_controls":true,"present_upsizing":true,"present_pointer":true,"present_notes":true,"default_deck_tag_id":null}},"background_transition":"fade","transition":"fade","theme_id":null,"theme_font":"opensans","theme_color":"white-blue","auto_slide_interval":0,"comments_enabled":false,"forking_enabled":true,"rolling_links":false,"center":false,"shuffle":false,"should_loop":false,"share_notes":false,"slide_number":true,"slide_count":56,"rtl":false,"version":2,"collaborative":false,"deck_user_editor_limit":3,"data_updated_at":1640619502383,"font_typekit":"","font_google":"Cabin, Inter, DM Sans, Roboto","time_limit":null,"navigation_mode":"default","upsizing_enabled":true,"notes":{}}};


			// Use local fonts
			SLConfig.fonts_url = 'lib/fonts/';
		</script>

		<script src="lib/reveal.js"></script>
		<script src="lib/reveal-plugins.js"></script>
		<script src="lib/offline.js"></script>

		<!-- Initialize the presentation -->
		<script>
			Reveal.initialize({
				width: 1024,
				height: 576,
				margin: 0.05,
				

				hash: true,
				controls: true,
				progress: true,
				mouseWheel: false,
				showNotes: false,
				slideNumber: true,
				fragmentInURL: true,

				autoSlide: 0,
				autoSlideStoppable: true,

				autoAnimateMatcher: SL.deck.AutoAnimate.matcher,

				center: false,
				shuffle: false,
				loop: false,
				rtl: false,
				navigationMode: "default",

				transition: "fade",
				backgroundTransition: "fade",

				highlight: {
					escapeHTML: false
				},

				plugins: [ RevealZoom, RevealNotes, RevealMarkdown, RevealHighlight ]
			});
		</script>

		

	</body>
</html>
